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LONGITUDINAL HISTOPATHOLOGICAL, IMMUNOHISTOCHEMICAL, 
AND IN SITU HYBRIDIZATION ANALYSIS OF HOST AND VIRAL 
BIOMARKERS IN LIVER TISSUE SECTIONS OF EBOLA (EBOV) 
INFECTED RHESUS MACAQUES  
ALEXANDRA GREENBERG 
ABSTRACT 
INTRODUCTION: Ebola virus (EBOV) is a highly infectious and often lethal filovirus that 
causes hemorrhagic fever, with a reported case fatality rate of 40–90%. There are currently no 
Food and Drug Administration (FDA) approved medical countermeasures (MCMs) for EBOV. 
Non-human primates (NHPs) remain the gold standard animal model for EBOV research as they 
most accurately recapitulate human disease.  
OBJECTIVE: This study aimed to characterize the temporal viral pathogenesis of EBOV in the 
liver of infected rhesus macaques using routine histopathology, multiplex immunohistochemistry 
(mIHC) and multiplex fluorescent In Situ Hybridization (mFISH), refined by digital pathology 
(DP) and image analysis (DIA).  
METHODS: 21 FFPE liver sections from EBOV-infected rhesus macaques were examined 
microscopically (Uninfected controls n=3; 3 DPE n=3; 4 DPE n=3; 5 DPE n=3; 6 DPE n=3; 
Terminal n=6). Tissues were stained with H&E and PTAH for histopathological scoring. Three 
serial sections were fluorescently immunolabeled or hybridized under three independent 
conditions (1.EBOV VP35, Tissue Factor, CD68; 2.EBOV VP35, Heppar, Myeloperoxidase 
(MPO); 3.EBOV VP35, IL-6, ISG-15). Slides were digitized by a Vectra PolarisTM fluorescent 
whole slide scanner and DIA was conducted using HaloTM image analysis software. Statistical 
analysis was conducted using GraphPad PrismTM 8.0. 
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RESULTS: Comparing peracute (3-4 DPE) to acute (5-6 DPE) and terminal (6-8 DPE) 
EBOV infection, there is a statistically significant (p < 0.05) increase in hepatic 
inflammation and fibrin thrombi, correlating with an absolute increase in macrophages (CD68), 
neutrophils (MPO), and total % of Tissue Factor in the liver. There is also a significant increase 
in the severity of necrosis, which correlates with a decrease in Heppar. While there was 
significant colocalization of VP35 and CD68 starting at 4 DPE, there was only rare colocalization 
of VP35 with Heppar, even in terminal animals. Similar to mIHC, progressive and statistically 
significant differences were observed in gene expression when comparing peracute to acute 
and terminal EBOV infection. IL-6 predominated within periportal fibrovascular compartments, 
but also colocalized within cells concurrently expressing EBOV VP35. EBOV VP35 expression 
was observed within histiocytes, endothelial cells, and less commonly hepatocytes. ISG-15 
expression was observed in periportal regions and in proximity to cells expressing EBOV VP35, 
but colocalization within EBOV VP35 expressing cells was an extremely rare event.  
CONCLUSION: Qualitative tools are well suited for confirming virulence and viral tissue 
tropism, but do little to build on our current understanding of disease. Using DIA in partnership 
with mIHC and mFISH, this study quantified statistically significant temporal changes in the 
immunoreactivity and hybridization of host and viral biomarkers that have previously been linked 
to the pathogenesis of EBOV. Taken together, these tools have enabled us to characterize minute 
changes that reflect magnitudes of biological variability simply not feasible to detect with the 
human eye. Furthermore, spatial context has refined our current understanding of differential 
gene expression of EBOV, which has the potential to aid in development of host-directed 
therapies. The establishment of these benchmarks will serve as a guide for the validation of cross-
institutional EBOV animal models. 
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INTRODUCTION 		
 Ebola virus (EBOV) is a highly infectious and often lethal filovirus that causes 
hemorrhagic fever, with a reported case fatality rate of 40-90% (Mühlberger & Hensley, 
2017; Speranza et al., 2018). The high variability in case fatality has been attributed to 
differences in virulence across different species and strains of EBOV, and variations in 
case reporting and case management (Lefebvre et al., 2014). EBOV transmission in 
competent host species occurs through direct exposure via broken skin and/or mucosal 
surfaces to infected body fluids (i.e. vomitus, diarrhea, semen, etc.), typically after and 
not during the incubation period (Meyers et al., 2015). Early clinical manifestations 
include non-specific flu-like symptoms such as fever, chills, diarrhea, dehydration, fever 
and lymphadenopathy. Disseminated intravascular coagulation (DIC), is a late-stage 
sequelae in humans and NHPs, which typically manifest between 6-10 days post-
infection and is clinically represented by prolonged PT (pro-thrombin) and PTT (partial 
thromboplastin time) times, thrombocytopenia, and cutaneous, mucosal, and alimentary 
petechial and echymotic hemorrhages. The cause of DIC is multifactorial, and ultimately 
is attributed to a combination of endothelial dysfunction and enhanced vascular 
permeability, activation of the coagulation cascade with microvascular fibrin thrombosis, 
depletion of platelets and clotting factors, hepatocellular degeneration and necrosis 
resulting in decreased production of clotting factors, and a generalized pro-inflammatory 
state driven by inflammatory cytokines and chemokines including IL-1, IL-6, IL-8, INF-a 
and TNF-a (Hutchinson & Rollin, 2007). In severe cases, disease progression leads to 
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hypovolemic shock, sepsis, multiple organ failure, and death (Geisbert et al., 2003a; El 
Sayed et al., 2016). There are currently no Food and Drug Administration (FDA) 
approved medical countermeasures (MCMs) for EBOV prevention or treatment (Lin et 
al., 2015; Mühlberger & Hensley, 2017; Nakayama & Saijo, 2013) although there are an 
increasing number of experimental vaccines and post-exposure countermeasures 
currently under development (Hayden, Bausch, & Friede, 2017).  
Due to the magnitude and widespread distribution of the 2013-2016 West African 
EBOV outbreak, there has been an unprecedented urgency to improve our knowledge of 
EBOV pathogenesis, as well as to enhance our ability to develop and validate the safety 
and efficacy of novel diagnostic tests, vaccines, and therapeutic interventions 
(Mühlberger & Hensley, 2017). The 2013-2016 outbreak was the largest EBOV outbreak 
to date, declared a Public Health Emergency of International Concern by the World 
Health Organization, with over 28,500 cases, greater than ten times the cumulative cases 
from all past Ebola outbreaks combined. There were more than 11,000 deaths reported 
across fifteen countries, which came with exceptional social, economic, and political 
costs (Mühlberger & Hensley, 2017). The never-before-seen scale of this outbreak was in 
part due to lack of healthcare infrastructure and resources in affected countries, 
insufficient and unprepared local healthcare workforce, and the spread of the virus into 
densely populated urban centers and eventually, across borders (Buseh et al., 2015). As 
the world becomes more and more interconnected, outbreak containment for highly 
infectious diseases like Ebola will become a greater challenge than ever before, making it 
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paramount that governmental and private appropriations continue to fund research aimed 
at developing and validating the safety and efficacy of MCMs.  
 
 
Experimental Therapeutics for EBOV  
 
Before 2013, scientific research on efficacy of EBOV prevention and treatment 
measures and pathogenesis studies were limited (Speranza et al., 2018). In 2002, the FDA 
established the “Animal Rule”. This new rule permitted the demonstration of efficacy for 
MCMs using animal studies in lieu of human clinical trials, in those instances where 
human trials would be unethical because of the serious clinical effects of the agent and 
where field trials would not be feasible because of the infrequency of human exposure to 
the agent. Preclinical development of MCMs in animal models is done through highly 
regulated and controlled studies, which facilitates collection of robust data sets to 
determine MCM efficacy. During the outbreak, clinical trials for promising vaccine 
candidates and monoclonal antibody therapies (Table 1), which had previously 
demonstrated efficacy in preclinical animal models, were accelerated in disease-affected 
countries, but only one trial demonstrated vaccine efficacy in humans (Mühlberger & 
Hensley, 2017; Espeland et al., 2018; Dhama et al., 2018). Given that clinical trials began 
late in the outbreak, it was not possible to reach statistically significant sample sizes for 
many of the studies before the outbreak ended. Furthermore establishing efficacy of 
MCMs in natural human outbreaks is inherently more challenging when comparing to 
animal models as the definitive time from inoculation to treatment, route of 
administration, or inoculation dosage cannot be determined and other confounding 
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variables, such as comorbidities and variation in the degree of local healthcare 
infrastructure and capacity are well established (Carter et al., 2018).  
Additionally, recent research has shown that virus persists in EBOV survivors 
through isolation from aqueous humor in patients with uveitis and semen from men 
weeks after resolution of clinical disease (Chughtai, Barnes, & Macintyre, 2016). 
Because of this, it is now recommended that any EBOV vaccine confer immunity for at 
least 2 years (Dhama et al., 2018). Demonstration of statistically significant long-lasting 
immunity following vaccination requires ongoing clinical trials, but trial length is 
typically dependent on the duration of outbreaks. There are currently new trials underway 
for EBOV vaccines and treatments, including monoclonal therapies and antivirals (Table 
1), in the Democratic Republic of Congo in response to a new outbreak that began in 
2018 (National Institute of Allergy and Infectious Diseases, 2018). 
While there are now experimental therapeutics available for EBOV and additional 
candidates undergoing animal and human testing, our understanding of EBOV viral 
pathogenesis and viral persistence in human survivors remains incomplete, which will 
likely be a challenge for approval of any MCMs under “Animal Rule”, due to the 
requirement to demonstrate mechanism of action of vaccines and drugs in animal models 
(Food & Drug Administration CDER, 2015). Continued pathogenesis research is 
therefore imperative to develop and adopt MCMs that can prevent and mitigate future 
public health emergencies due to the spread of EBOV. 
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Table 1. Experimental EBOV treatments and vaccines. 
Type of MCM Name Formulation and 
Target 
Company Trial(s) & Results 
VACCINES rVSV-
ZEBOV 
vaccine 
candidate 
(V920)  
Single dose Vesicular 
stomatitis virus 
(VSV)-based vaccine; 
targeting EBOV 
Glycoprotein (GP) 
Merck Phase III trial in 
Guinea; safe and 
effective in adults 
>18; rapid immune 
response sustained up 
to one year post-
vaccination 
 Ad26-
ZEBOV/M
VA-BN-
Filo 
vaccine 
candidates 
Prime-boost regimen; 
Adenovirus-based 
prime & modified 
vaccinia virus Ankara 
boost at 28 or 56 days; 
targeting EBOV GP & 
VP40 
Janssen Vaccines 
& Prevention 
B.V. in 
collaboration with 
Bavarian Nordic 
GmbH 
Phase III clinical 
trial, did not reach 
statistical 
significance 
 ChAd3-
EBO-Z 
vaccine 
candidate 
 
Single dose 
Adenovirus-based 
vaccine; targeting 
EBOV GP 
GlaxoSmithKline Phase II 
Ad-based vaccine 
given in combination 
with a booster dose of 
the MVA-BN-Filo 
vaccine candidate 
Bavarian Nordic 
GmbH 
 
Phase III trial; 
elicited B- and T-cell 
immune responses; 
did not reach 
statistical 
significance 
TREATMENTS ZMapp 3, chimeric 
monoclonal antibody 
(mAb) cocktail 
Mapp Biopharma-
ceutical 
PREVAIL II Phase 
I/II clinical trial in 
Guinea, Liberia, 
Sierra Leone, and the 
US; did not reach 
statistical 
significance but 
showed a trend 
towards efficacy 
 REGN-
3470-3471-
3479 
 
Fully human 3-mAb 
cocktail 
Regeneron Undergoing Phase I 
clinical study 
 Favipiravir Broad-spectrum 
antiviral active against 
RNA viruses 
Toyama Chemical Phase I/II Trial in 
Guinea, did not reach 
statistical 
significance  
 Remdesivir Antiviral drug Gilead Sciences Undergoing Phase I 
clinical study 
*Information in table adapted from Espeland et al., 2018 and Dhama et al., 2018. 
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Ebola Virus, Viral Pathogenesis, and Host Response  
EBOV is a single-stranded, negative-sense RNA virus, with the genome encoding 
seven structural viral proteins from the 5’ to 3’ end: nucleoprotein (NP), viral protein 35 
(VP5), viral protein 40 (VP40), glycoprotein (GP), viral protein 30 (VP30), viral protein 
24 (VP24), and RNA Polymerase (L). GP is the only structural protein expressed as a 
transmembrane protein on the virion surface, facilitating viral entry via host cell 
attachment, receptor binding, and membrane fusion within the endosome (Lee & Saphire, 
2009). EBOV viral RNA is encapsidated by nucleocapsid proteins to form a 
ribonucleoprotein (RNP) complex, which is the minimum replicative unit of EBOV. 
Polymerized nucleocapsids form filamentous EBOV viral particles composed of 5 EBOV 
structural proteins: NP, VP35, VP30, L and VP24. NP, VP35, and V24 are essential and 
sufficient to mediate nucleocapsid transport within the host cytoplasm (Takamatsu, 
Kolesnikova & Becker, 2018). NP encapsidates the genome, while VP35 is a polymerase 
cofactor, VP30 is a transcriptional activator, and RNA polymerase L facilitates genome 
replication and transcription. VP24 facilitates RNP assembly (Baseler et al., 2017). VP40 
is a membrane-associated matrix protein, which regulates viral transcription, coordinates 
RNP and virion assembly in host cells, and facilitates viral budding from infected cells 
(Madara et al., 2015). Additionally, VP35 and VP24 have been shown to inhibit the 
immune response by blocking interferon production and signaling (Lubaki et al., 2016). 
VP35, which is the second most abundant EBOV protein, has been shown in recent 
studies to have additional functions that interfere with the early innate immune response 
(Baseler et al., 2017), making it a useful marker for quantification of EBOV and 
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comparison with interferon activity in infected animals. 
Recent studies, in addition to providing insight into the EBOV genome and viral 
structure, have shed new light on how EBOV infection is established and how the virus 
disseminates in the body. Research in both humans and non-human primates has shown 
that following infection, EBOV spreads through blood vessels and lymphatics, likely via 
monocytes, macrophages and dendritic cells, which have previously collectively been 
referred to as the mononuclear phagocytic system (MPS), with subsequent endothelial 
replication and dissemination to sites of secondary viral replication, specifically the 
lymph nodes, spleen, and liver (Martines, et al., 2014; Mühlberger & Hensley, 2017). 
EBOV causes widespread immune dysregulation with upregulation of interferon (IFN) 
and IFN-stimulated genes (ISGs), including ISG-15, release of cytokines and 
chemokines, including interleukin-6 (IL-6), and impairment of the innate immune 
response (Speranza & Connor, 2017; Caballero et al., 2016).  
ISG-15 and IL-6 were selected for use in this study based on published and 
ongoing research at the NEIDL that indicates significant global upregulation of these 
genes in response to EBOV infection in vitro and in vivo (Speranza & Connor, 2017), as 
well as availability of biomarker reagents for multiplex fluorescent In Situ Hybridization. 
IFN-stimulated gene-15 (ISG-15) is an antiviral ubiquitin-like protein expressed by both 
immune and non-immune cells, found both freely intracellular and as a protein modifier 
extracellular, that has been shown to inhibit ubiquitination of Ebola VP40 protein and 
subsequently prevent viral budding in vitro in human cells (dos Santos & Mansur, 2017; 
Hermann & Bogunovic, 2017). IL-6 is a cytokine produced by various immune and non-
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immune cells for host defense in response to infection and tissue injury (Tanaka, 
Narazaki, & Kishimoto, 2014). IL-6 has pro-inflammatory effects, particularly in the 
liver, where it stimulates production of C-reactive protein, serum amyloid and fibrinogen 
and reduces production of fibronectin, albumin, and transferrin. IL-6 contributes to 
increased platelet production and thrombocytosis and when its production is upregulated, 
contributes to cytokine storm, similar to what has been seen in EBOV (Tanaka, Narazaki, 
& Kishimoto, 2014; Hellman, 2015). IL-6 has also been shown to induce synthesis of 
Tissue Factor (TF) by human peripheral blood monocytes (PBMCs) and PBMCs have 
been found to increase production of TF during EBOV (Blackwell Science Ltd, 2001; 
Geisbert et al, 2003b). TF is the membrane receptor for coagulation factors VII and VIIa 
and is responsible for initiation of the external coagulation cascade. It can be found on 
multiple cell phenotypes and plays an essential role in thrombosis and inflammation. In 
EBOV it has been shown to increase significantly, leading to accumulation of fibrin and 
contributing to development of DIC (Geisbert et al., 2003b). Following EBOV infection, 
changes are also observed in complete blood count (CBC) including lymphopenia, 
thrombocytopenia and neutrophilia. Eventually, this can be followed by multi-organ 
failure and death 1-to-2 weeks post-symptom onset, although factors contributing to 
variations in disease severity are poorly understood (Nakayama & Saijo, 2013; Speranza 
et al., 2018).  
While the spleen is also a major site of viral replication, with a large resident 
macrophage cell population, terminal disease in NHPs corresponds with peak viral loads 
in the liver associated with hepatocellular degeneration and necrosis (Martines et al., 
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2014; Spengler et al., 2017). Gross findings of EBOV infection include an enlarged pale 
friable liver. This is histologically characterized by kupffer cell hyperplasia, hepatocyte 
degeneration and necrosis, and intracytoplasmic inclusion bodies that represent viral 
nucleocapsid aggregates. Clinical laboratory tests show an initial increase in liver leakage 
enzymes aspartate transaminase (AST) and alanine transaminase (ALT), followed by 
prolonged clotting times (PT and PTT), and decreased albumin and total protein. These 
findings are suggestive of hepatocellular injury and decreased liver function respectively; 
albeit hypoalbuminemia is also likely attributed to loss in fluids if supported clinically 
(i.e. vomiting and diarrhea). Additional findings include azotemia represented by rising 
blood urea nitrogen (BUN) and creatinine, which is primarily attributed to pre-renal 
disease/dehydration caused by hypovolemia. Renal tubular necrosis has also been 
observed microscopically indicating direct renal disease also may play a role in azotemia 
(Cooper et al., 2018; Lin et al., 2015; Martines et al., 2014). Recent studies have shown 
that increased viral titers in the liver (quantified via RT-PCR) and markedly elevated 
AST levels are associated with lower EBOV survival rates (Reisler et al., 2017; Speranza 
et al., 2018). Yet, viral replication in hepatocytes remains poorly characterized and 
discrete histopathological changes in the liver have not previously been investigated 
longitudinally and quantified in NHPs or in vitro models of primary hepatocyte cell lines 
(Spengler et al., 2017). 
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Animal Models of EBOV  
Due to ethical concerns, the classification of EBOV as a select agent, requirement 
of Biosafety Level 4 (BSL-4) containment, and the sporadic and unpredicted nature of 
outbreaks, studies on both human and animal samples for EBOV infection have been 
limited (Martines et al., 2014). Research on EBOV pathogenesis, particularly in the liver, 
has been conducted in various animal models, including humanized mice, guinea pigs, 
ferrets, and NHPs, specifically baboons, marmosets, cynomolgus macaques and rhesus 
macaques (Martines et al., 2014; Perry, Bollinger, & White, 2012; Smither et al., 2015). 
Routes of viral inoculation utilized in animal models have included intramuscular, 
conjunctival, oral, aerosol and intranasal (Cooper et al., 2018; Martines et al., 2014; 
Reisler et al., 2017; Spengler et al., 2017; Speranza et al., 2018; Johnson et al., 1995). 
NHPs represent the gold standard for EBOV research, given their high fidelity to 
recapitulate human disease pathophysiology. NHPs do not require viral adaptation and 
typical signs include the development of a macular rash, petechial and ecchymotic 
hemorrhages, coagulation abnormalities, elevated liver enzymes, thrombocytopenia, 
lymphocytopenia, and robust pro-inflammatory cytokine responses (Hoenen et al., 2006).  
With the exception of a single longitudinal study in cynomolgus macaques 
(Geisbert et al., 2003a), the majority of NHP studies have examined the terminal stage or 
chronic clinically resolved stages of EBOV disease (Lin et al., 2015; Nakayama & Saijo, 
2013). Microscopically, the temporal and spatial progression of EBOV in the liver from 
initial viral replication to death or recovery has yet to be characterized. Little is known 
about what causes inter-host variability in EBOV infection, although EBOV severity has 
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been linked to increased viral load in the liver (Reisler et al., 2017). Further research is 
warranted concerning hepatocellular dysfunction and death in EBOV and mechanisms of 
EBOV driven aberrations of host-immune response in the liver. 
Well-characterized models of EBOV infection are indispensable for the 
development of MCMs, given that their approval will likely require use of the FDA’s 
“Animal Rule” (Mühlberger & Hensley, 2017). There are four criteria that must be met 
for “Animal Rule” to be used to approve MCMs based on animal studies (Table 2), one 
of which is that the pathophysiology of EBOV must be well understood and proven to be 
consistent across the model(s) used and in humans (Snoy, 2010).  
 
Table 2. Animal Rule Criteria as defined by the FDA. 
(1) Mechanism of Action for MCM is 
clear 
“There is a reasonably well-understood 
pathophysiological mechanism of the toxicity of the 
substance and its prevention or substantial reduction by 
the product.” 
(2) Multiple animal models (or one 
animal model with high fidelity to 
human disease pathogenesis) 
demonstrate effect of MCM  
“The effect is demonstrated in more than one animal 
species expected to react with a response predictive for 
humans, unless the effect is demonstrated in a single 
animal species that represents a sufficiently well-
characterized animal model for predicting the response 
in humans.” 
(3) Same endpoint used in animal 
study as desired in humans 
“The animal study endpoint is clearly related to the 
desired benefit in humans, generally the enhancement 
of survival or prevention of major morbidity.” 
(4) Pharmacokinetics and 
pharmacodynamics in animal 
model(s) can be extrapolated to 
humans 
“The data or information on the kinetics and 
pharmacodynamics of the product or other relevant data 
or information, in animals and humans, allows selection 
of an effective dose in humans.” 
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Rodents, including mice and hamsters, require viral adaptation or 
immunosuppression to cause clinical disease and do not exhibit all of the hallmarks of 
EBOV host-response as observed in humans and NHPs, making them suboptimal models 
for evaluating MCMs. For example, mice infected with mouse-adapted EBOV, unlike 
humans and NHPs, do not develop DIC and in guinea pigs that do exhibit fibrin 
deposition and coagulopathy, it is much less severe than in humans and NHPs 
(Nakayama & Saijo, 2013). NHPs such as rhesus macaques present their own ethical and 
logistical challenges, which include consistently higher case fatality rates than humans, 
and are expensive and cumbersome to work with, but remain the gold standard model for 
characterizing the pathogenesis of EBOV and for evaluating MCMs.  
Given the inherent challenges of working with animal models, a demand for 
novel, more convenient and affordable disease models for EBOV are desired. Limitations 
for existing in vitro models using immortalized human hepatocytes, such as the Huh7 
human hepatocarcinoma cell line, include the absence of TLR4 expression (an important 
innate pathogen pattern recognition receptor for EBOV) and the absence of a robust 
interferon response when infected with EBOV (Preliminary data, Mühlberger Lab, 
NEIDL). Preliminary partnership studies with the CReM and NEIDL have shown that 
primary hepatocytes derived from induced pluripotent stem cells (iPSCs) and liver 
organoids more faithfully recapitulate the host-viral responses observed in natural 
disease, including a robust interferon and cytokine response. These novel in vitro 
platforms will be invaluable resources for investigating basic science research and will 
propel translational studies using animal models (Bennett et al., 2017).  
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Specific Aims 	
The purpose of this study was to characterize the pathogenesis of acute in vivo 
Ebola (EBOV) infection in the liver of infected rhesus macaques. The ultimate goal was 
to characterize the host response signature to EBOV infection over time, which can then 
serve as a benchmark for novel models such as iPSCs, liver organoids, and a platform for 
evaluating efficacy of EBOV MCMs, including vaccines and antiviral therapies. This 
work used digital image analysis to provide novel insights into the organ-specific host 
response to EBOV. 
 
Experiments were conducted to: 
1) Characterize histomorphological features of EBOV in the liver utilizing routine 
hematoxylin and eosin and Phosphotungstic Acid-Hematoxylin (PTAH) staining 
2) Quantify the temporal spread of viral infection within unique hepatic 
compartments utilizing multiplex immunofluorescence  
3) Quantify host gene expression of cellular pathways involved in pro-inflammatory 
and innate immunity in response to EBOV 
 
Below are histopathological, immunohistochemical, and In Situ hybridization 
findings collected from a group of 21 rhesus macaques. Data was obtained from liver 
samples provided by the National Institute of Allergy and Infectious Diseases Integrated 
Research Facility (NIAID IRF). 
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METHODS  
 
 
Animals and Method of Infection  
The NHP tissue samples used in this study (Table 3) were collected by the NIAID 
IRF under Battelle Memorial Institute Contract No. HHSN272200700016I and provided 
for use at the NEIDL under the Interagency agreement NOR 15 003 -001-0000. The IRF 
conducted a challenge study to explore EBOV Kikwit natural history with 27 rhesus 
macaques of Chinese origin. Our laboratory reviewed samples collected during scheduled 
or terminal endpoint-triggered necropsy from 3 control animals and 18 EBOV infected 
macaques, six of which were terminal (6-8 DPE). Euthanasia criteria for terminal animals 
were developed prior to study start and only clinical signs were used in the euthanasia 
decision. No secondary hematology or chemistry values were utilized. Clinical signs of 
appearance, respiration, recumbency, and non-responsiveness were scored on a 
predetermined scale (Appendix I). When the score total was 8 or 9, the PI or a co-
investigator consulted with the facility veterinarian and a decision was made regarding 
euthanasia. Animals were euthanized immediately when a total score of  ≥ 10 was 
reached. Animals that were moribund, as evidenced by a core temperature below 34°C 
(<93°F), or were in severe respiratory distress were also euthanized immediately.  
Under BSL-4 conditions at the NIAID IRF, animals were exposed to 
EBOV/Kikwit isolate diluted to a target concentration of 1,000 PFU in a volume of 1 mL 
/dose. Injections were delivered intramuscularly into the left lateral triceps muscle on 13-
DEC-2017, 03-APR-2018, 06-MAY-2018, and 17-MAY-2018 for challenge groups 1-4, 
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respectively. The injection site was consistent across all NHPs and marked for tissue 
collection at necropsy. Control animals were not injected with EBOV/Kikwit. 
EBOV/Kikwit-exposed animals were observed for the development of clinical signs of 
EBOV infection and, to allow for temporal analysis of EBOV pathogenesis post-
infection, were humanely euthanized either at terminal endpoints (6-8 DPE) or at 
predetermined time points (3-6 DPE) before a necropsy was performed.  
 
Table 3. Non-human primates used in this study (excludes Challenge Group 1). 
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For this follow-on study, only Challenge Group 2 Terminal animals as well as 
Group 3 and 4 scheduled necropsy animals were evaluated. Liver samples were collected 
during a scheduled or terminal endpoint-triggered necropsy in bead beater tubes with 
TRIzoI or as formalin-fixed tissue blocks to measure interferon responses in these tissues. 
All animals were humanely euthanized in accordance with defined experimental 
endpoints and gross necropsy was performed. The requested tissues were collected (at 
least one dimension <1 cm) and were inactivated according to IRF SOP SF-24 in the 
NIAID IRF BSL-4 facility. Samples were fixed for 72 hours in 10% neutral buffered 
formalin, after which a buffer exchanged was performed, removed from the BSL-4 
laboratory, processed in a Tissue-Tek VIP-6 automated vacuum infiltration processor 
(Sakura Finetek USA, Torrance, CA, USA), followed by paraffin embedding with a 
Tissue-Tek model TEC unit (Sakura Finetek USA, Torrance, CA, USA). Once 
inactivated, tissue samples were treated as non-infectious and all subsequent 
histopathological staining and analysis was performed in BSL-2 conditions at the NEIDL.  
 
Brightfield histopathological preparation and evaluation 
5 μm histology sections were prepared using formalin-fixed paraffin-embedded 
(FFPE) tissues from the liver, cut using a Leica RM2255 Fully Automated Rotary 
Microtome. Tissue samples were deparaffinized in xylene and rehydrated in a graded 
ethanol series followed by washing in distilled water. All slides were stained with 
hematoxylin and eosin (H&E) before mounting. Phosphotungstic acid-haematoxylin stain 
(PTAH) was used on some liver sections to confirm fibrin deposition suspected based on 
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H&E findings. Brightfield images were captured with a Leica DM2500 LED microscope 
at 400x (dry) - 600x (oil immersion). 
All slides were reviewed for specific microscopic features to determine pathologic 
changes across time points and assess inter-animal variability. Dr. Nicholas Crossland, a 
board-certified veterinary pathologist, performed scoring based on severity of these 
features, while blinded to clinical and biochemical data for each specimen. Based on 
preliminary observations, definitions were set for semi-quantitative, ordinal or binary 
scores to use for progression of specific morphological features in the liver and overall 
severity of organ-specific histopathological changes. Parameters evaluated were degree 
of inflammation, necrosis, and fibrin deposition as well as presence or absence of 
intracytoplasmic eosinophilic viral inclusions. A composite score was assigned for each 
animal based on the sum of the values assigned for each individual evaluated parameter 
(Table 4). 
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Table 4. Criteria used for Histopathological Scoring of the liver. 
 
 
	
Necrosis						0	(Absent)	 	 	 No	necrosis					1	(Minimal)	 Rare	multifocal	single	cell	necrosis	adjacent	to	sinusoidal	histiocytic	inflammation	2	(Mild)	 Multifocal	necrosis	of	neighboring	hepatocytes	;	more	widespread		3	(Moderate	to	marked)		 Multifocal	coalescing	areas	of	hepatocellular	loss	(absence	of	hepatocytes	in	large	areas	replaced	by	fibrin,	edema,	hemorrhage	and	inflammatory	cells)	
Inflammation					0	(Absent)	 	 	 No	inflammation					1	(Mild)	 Rare,	multifocal,	localized	inflammation	within	sinusoids	consisting	of	aggregated	histiocytes	and	neutrophils	2	(Moderate)	 Sinusoidal	expansion	by	>	5	neighboring	histiocytes	admixed	with	variable	numbers	of	neutrophils	3	(Severe)		 Inflammatory	foci	consisting	of	neutrophils	admixed	with	histiocytes	and	fibrin	in	areas	of	hepatocellular	loss	(necrosis)	
Fibrin	deposition					0	(Absent)	 	 	 No	fibrin	deposition	evident					1	(Mild)	 Rare,	multifocal	occlusion	of	sinusoids	by	fibrin		2	(Moderate)	 Routine,	multifocal	occlusion	of	sinusoids	and	veins	by	fibrin	thrombi		
Inclusions					0	(Absent)	 	 	 No	viral	inclusions	observed						1	(Present)	 	 	 Eosinophilic	cytoplasmic	viral	inclusions	observed		
 
Statistical Analysis for Brightfield Histopathology 
For liver semi-quantitative histopathological scores, given the ordinal nature of 
the data, the non-parametric Kruskal Wallis test was used to evaluate for statistical 
significance between days post-exposure (DPE) and histology scores over time across the 
six unmatched groups (Control, 3 DPE, 4 DPE, 5 DPE, 6 DPE, and Terminal/7-9 DPE). 
The two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli was applied, 
threshold (α rate of 0.05), a priori to correct for multiple comparisons. GraphPad Prism 
8.0 was used for all statistical tests and formulation of graphical depictions of results. 
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Multiplex Fluorescent Immunohistochemistry (mIHC) 
Multiplex fluorescent immunostaining was conducted following the OpalTM 4-
color User Manual (Akoya Biosciences, Menlo Park, CA, USA). Independent 3-plex 
immunohistochemistry panels were developed, optimized and applied on serial sections 
of liver derived from each of the 21 animals outlined in this study, prepared via the same 
workflow used for brightfield slides. Antibodies included EBOV VP35 and a 
combination of liver associated host proteins, known to differentiate specific anatomical 
compartments and/or cell types (Table 5).  
Before mIHC was performed, individual antibodies were optimized via single-
plex IHC with each primary antibody on 9 liver section slides. Three slides were stained 
with the manufacture’s recommended primary dilution and there were 3 slides each with 
two-fold and 4-fold dilutions. For each dilution, 1, 2 and then 3 ARs were performed on 
different slides to evaluate the influence of repeated antigen retrieval (AR) for the given 
antibody. Images were taken of each slide using the same exposure time to select the 
optimal primary antibody dilution, the dilution with the most specific and broadest 
dynamic range, and to determine the final order of antibodies for mIHC (Table 5). 
For mIHC, 5 µM tissue sections were cut from FFPE liver samples from each 
non-infected and EBOV infected rhesus macaques. Tissues were then deparaffinized and 
soaked in 10% formalin for 20 minutes before undergoing heat-mediated antigen retrieval 
(AR) using AR6 buffer and a steamer set to 100° C to ensure uniform heating of the 
tissue. Subsequent heat-mediated ARs were also performed under these conditions. Slides 
were incubated in antibody diluent/blocking agent for 10 minutes to block endogenous 
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peroxidase activity. Then primary antibodies for the given 3-plex mIHC were applied at 
the concentration and in the order determined through optimization, followed by 
visualization (Table 5). 
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Table 5. Optimized mIHC conditions. 
*mIHC-3 (Appendix II) is not included because, while WSIs were collected, DIA could not be performed.
Condition Primary 
Antibody 
Animal and 
Isotype 
Tissue 
marker 
Manufacturer, 
Catalog # and 
Lot # 
Concen-
tration 
TSA-conjugated 
Fluorochrome 
Manufacturer, 
Catalog # and 
Lot # 
Concen-
tration 
AR 
1 Anti-Zaire 
Ebola VP35 
Ms IgG2b EBOV Viral 
particles 
Kerafast 
EMS703 
090315 
1/300 Green (Opal 520) PerkinElmer 
FP1487A 
2380385 
1/400 1 
 Heppar 
(OCH1E5) 
Ms IgG1 Hepatocytes ThermoFisher 
MA5-12417 
TD2559592A 
1/50 Far red (Opal 690) PerkinElmer 
FP1497A 
2491340 
1/100 2 
 Myelo-
peroxidase 
(MPO) 
Rb IgG Neutrophils ThermoFisher 
PA5-16672 
TE2572301G  
1/200 Red (Opal 570) PerkinElmer 
FP1488A 
2496488 
1/200 3 
2 VP35 Ms IgG2b EBOV Viral 
particles 
Kerafast 
EMS703 
090315 
1/300 Green  PerkinElmer 
FP1487A 
2380385 
1/400 1 
 CD68 Ms IgG1 Monocytes/ 
Macrophages 
Dako 
M081401-2 
20047711 
1/50 Far red PerkinElmer 
FP1497A 
2491340 
1/100 2 
 Tissue Factor 
(CD142,  
TF9-10H10) 
Ms IgG1 Extrinsic 
Coagulation 
pathway 
ThermoFisher 
MA1-83495 
TI2638538 
1/50 Red PerkinElmer 
FP1488A 
2496488 
1/200 3 
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Fluorescent In Situ Hybridization (FISH) 
Fluorescent In Situ hybridization (FISH) was conducted following the RNAscope 
Multiplex FL v2 User Manual (Advanced Cell Diagnostics, Hayward, CA, USA). The 
same day as the FISH assay, 5 µM sections of FFPE liver tissue samples were cut and 
prepared to limit RNA degradation. Samples were deparaffinized and pretreated with 
hydrogen peroxide for 10 minutes to block endogenous peroxidase activity, followed by 
heat-mediated target retrieval using a steamer set to 100° C for 15 minutes. This was 
followed by RNAscope Protease Plus incubation in the ACD Hybez II Oven for 30 
minutes. The target probes were then applied to the samples for hybridization with a two-
hour incubation in the oven followed by signal amplification and probe visualization 
(Table 5). A positive control probe was included to confirm integrity of sample RNA and 
a negative control probe was included to confirm specificity of staining. The positive 
control probe was a marker known to stain the housekeeping gene Vegfa in macaque 
tissue (Advanced Cell Diagnostics, Cat # 487211, Lot # 18143A) and the negative 
control probe was for the non-specific bacterial gene DapB of Bacilus subtilis (Advanced 
Cell Diagnostics, Cat. # 310043, Lot # 17264A). 
 
 
 
 
 
 
	23 
Table 6. FISH target probes and visualization. 
 
 
  
 Probe mRNA 
marker 
Manufacturer, 
Catalog # and 
Lot # 
HRP-
conjugated 
Fluorochrome 
Manufacturer, 
Catalog # and 
Lot # 
Conc. 
C1 Mmu-
ISG1501 
Interferon-
stimulated 
gene 15 
Advanced Cell 
Diagnostics 
540521 
18136A 
Far red (Opal 
690) 
PerkinElmer 
FP1497A 
2491340 
1/750 
C2 Hs-IL6-
C2 
Interleukin 
6 
Advanced Cell 
Diagnostics 
310371-C2 
18270A 
Red (Opal 570) PerkinElmer 
FP1488A 
2496488 
1/750 
C3 V-Ebola-
VP35-C3 
EBOV Viral 
Protein 
VP35 
Advanced Cell 
Diagnostics 
451691-C3 
18116B 
Green (Opal 
520) 
PerkinElmer 
FP1487A 
2380385 
1/750 
 
 
Whole Slide Scanning and Digital Image Analysis for mIHC & FISH 
 All mIHC and FISH slides were digitized at 200x via fluorescent multispectral 
imaging with the Vectra Polaris Automated Quantitative Pathology Imaging System 
(Akoya Biosciences), equipped with an LED light source and monochrome camera. 
Acquisition parameters are outlined in Table 6. Terminal animal tissue samples were 
used to optimize exposures for each assay, via auto-exposure on a region of interest 
(ROI) and scanning to ensure parameters were correct. Then remaining slides for that 
assay were batch loaded and digitized, with parameters selected using the auto-exposure 
and auto-focus features on an ROI of the slide, and correction for any slide parameters 
outside of the range set based on terminal animals (no more than 3X channel exposure for 
terminal animals, except for green channel < 30 ms; Table 7).  
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Table 7. Optimized WSI scanning exposures. 
 
Condition Exposure 
Range 
mIHC-1 
DAPI 2 – 5 ms 
Opal 570 25 – 75 ms 
Opal 690 30 – 90 ms 
Opal 520  5 – 30 ms 
mIHC-2 
DAPI 2 – 5 ms 
Opal 570 25 – 75 ms 
Opal 690 30 – 90 ms 
Opal 520  5 – 30 ms 
FISH (less variable) 
DAPI 2 – 5 ms 
Opal 570 50 – 75 ms 
Opal 690 25 – 40 ms 
Opal 520  3 – 7 ms 
 
Digitized whole slides were analyzed using image analysis software (HALOTM, 
Indica Labs, Inc., Corrales, NM). Slides were first manually annotated to remove tissue 
artifacts (i.e. folds, air bubbles, fluorescent precipitate, etc.) and to select the tissue 
ROI(s) for digital analysis (Figure 2). Histogram threshold values were modified in 
viewer settings to minimize background signal and improve visibility of biomarkers 
within the real-time tuning window. For mIHC slides, quantitative outputs were derived 
from the Area Quantification FL (AQ) and High-Plex FL (HP) modules. For tissue 
ROI(s) included for analysis, Area Quantification FL reports total area positivity as a 
percentage and total tissue area (µm²) for up to three fluorescent dyes used, as well as 
total area and percent positivity for 2 or more dyes (merged or overlapping dyes). High-
Plex FL outputs include the absolute number of cells as well as cellular phenotyping for 
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cells expressing two or more fluorescent dyes within a defined cellular compartment. For 
both modules, minimum dye intensity thresholds were established for dye detection 
(Figure 1A). In order to accurately detect cells within tissue samples, in addition to dye 
thresholds, HP requires setting of nucleus, membrane and cytoplasm detection thresholds 
and ranges (Figure 1B-D). 
 
                                                       
 
Figure 1: HaloTM Area Quantification FL and High-Plex FL Module parameters. 
(A) AQ parameters to set for each dye (marker) 
(B) All HP parameters, (C) HP Nucleus Detection parameters (D) HP Membrane and 
Cytoplasm Detection parameters 
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Module parameters were set for AQ and HP using real-time tuning, field of view 
and whole slide analysis, which were done at 1.5 magnification. For both modules, 
thresholds were set for minimal intensity for each fluorescence dye using terminal 
animals and real-time tuning of an ROI with targeted differential staining visualized. 
Then terminal settings were loaded and parameters were refined for each individual slide 
from earlier time points based on knowledge of anatomical specificity of liver 
biomarkers. For AQ, WSIs, with annotations to remove artifacts, were analyzed. For HP, 
given difficulties encountered in applying the HP Module for WSI analysis, a 10x field of 
view was analyzed on each slide to quantify number of cells per µm². 
After running modules with initial annotations and thresholds, adjustments were 
made based on preliminary whole slide output images. To minimize variation across 
conditions for mIHC, cell detection and dye threshold parameters were set for the HP 
module using condition 1 and then these settings were imported, once finalized, for 
condition 2 analyses. Threshold parameters were then refined further using real-time 
tuning, if not already at the most accurate value to maximize specificity and sensitivity of 
the algorithm. Dr. Crossland, given his expertise as a trained veterinary pathologist, 
assisted with setting appropriate and accurate parameters for all modules and reviewed 
final annotations, parameters, modules, and resulting analyses. This iterative process of 
running, re-tuning, validating, and confirming modules before finalizing results was 
undertaken with the goal of improving reliability and accuracy of subsequent data 
analysis.   
Digital whole slide images (WSI) and associated annotations and analyses, with 
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their threshold and detection parameters, were uploaded to Dr. Crossland’s BU SCC 
laboratory storage and can be accessed upon request. 
       
 
 
 
Figure 2: HaloTM Digital Image Analysis workflow. 
(A) Imported whole slide image (WSI) scan in HaloTM, (B) Annotated whole slide scan 
with artifacts removed from region(s) of interest (ROI) that will be included in area for 
analysis, (C) 20x Field of view, unadjusted stained slide (D) Alteration of black and 
white balance and channel intensity to reduce background noise and increase sensitivity 
for analysis at selected thresholds, (E) Real-time tuning window for the HaloTM Area 
Quantification (AQ) FL module, (F) Real-timing tuning analysis mark-up, (G) 
Unannotated 20x field of view with false positive staining, (H)  Real-time tuning mark-up 
shows analysis of false-positive without annotation, (I) Field of view AQ mark-up with 
A B 
C 
D 
G H I 
E F 
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annotation to remove false-positive from ROI for analysis, colocalization indicated by 
change in color in areas of 2+ channel overlap 
 
 
 
Statistical Analysis for mIHC and FISH 
One-way analysis of variance (ANOVA) was used, given that mIHC and FISH 
results were quantitative and parametric, to determine if statistical significance existed for 
host and viral biomarker expression. One-way ANOVA was performed on percent area 
reactivity/hybridization for each biomarker to account for variations in tissue sample size. 
One-way ANOVA was also conducted on changes in percent of cells positive for certain 
markers over time per given area. Values were compared for each measure within and 
across all groups (control, DPE groups, and terminal) with post-hoc Tukey correction for 
multiple comparisons. Measurements were then compared for colocalization of markers 
percent area over time using these same tests. Changes were compared in different 
markers over time to one another to assess whether they were correlated using Pearson’s 
correlation coefficient (r). Quantitative results were also compared to ordinal 
histopathology scores using correlation coefficients to see if histopathological, 
immunohistochemical and In Situ hybridization findings were related. Simple linear 
regression was conducted of various parameters on ordinal scores and percent area VP35 
immunoreactivity. Both linear regression and correlation coefficients were used because 
of the ordinal nature of the data, to provide comparison in case of overfitting of data via 
simple linear regression since logistic regression is not available in GraphPad PrismTM 8. 
For all statistical analysis, P-values < 0.05 were considered statistically significant. 
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RESULTS 
  
Qualitative Histopathology 
The first distinct histomorphological feature attributed to EBOV disease was 
observed 3 DPE in one animal, which exhibited mild sinusoidal expansion by histiocytes 
(inflammation-1; Figure 3A) and rare histiocytic cytoplasmic viral inclusions (Figure 
4A). At 4 DPE, one animal exhibited histiocytic cytoplasmic viral inclusions, but 
displayed no evident inflammation or fibrin deposition, while the two remaining animals 
both exhibited mild sinusoidal expansion by histiocytes (inflammation-1), rare sinusoidal 
fibrin thrombi (fibrin-1; Figure 4D), and histiocytic cytoplasmic viral inclusions. By 5 
DPE, all animals exhibited minimal-to-mild multifocal hepatocellular necrosis (necrosis-
1 or 2; Figures 5B and C), rare to occasional sinusoidal fibrin thrombi (fibrin-1 or 2; 
Figure 4D and E), moderate expansion of sinusoids by histiocytes and neutrophils 
(inflammation-2; Figure 3B), and an increased frequency of cytoplasmic viral inclusions, 
which for the first time included both histiocytes and hepatocytes (Figure 4A and B).  
At 6 DPE, 2 of 3 animals displayed moderate hepatocellular necrosis (necrosis-2), 
with the remaining animal having mild hepatocellular necrosis. All 3 animals displayed 
moderate sinusoidal expansion by histiocytes and multifocal fibrin thrombi 
(inflammation-2, fibrin-2). At terminal time points, 5 of 6 animals displayed occasional 
sinusoidal fibrin thrombi (fibrin-2), with one animal displaying rare fibrin thrombi 
(fibrin-1). 4 animals had moderate expansion of sinusoids by histiocytes (inflammation-
2), while the remaining two animals had either severe inflammation consisting of 
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neutrophils and histiocytes (inflammation-3; Figure 3C), or rare sinusoidal aggregates of 
histiocytes (inflammation-1). Four of six terminal animals exhibited moderate 
hepatocellular necrosis (necrosis-2), while the remaining two animals had either severe 
hepatocellular loss (necrosis-3; Figure 5D) or rare scattered individual hepatocellular 
necrosis (necrosis-1; same animal with inflammation-1). 
 
    
 
 
 
 
Figure 3: Progression of inflammation in liver of EBOV-infected Rhesus Macaques.  
(A) 1 - Rare, increased numbers of histiocytes and neutrophils within sinusoids, 3 DPE, 
(B) 2 - Expansion of sinusoidal spaces by aggregates of >5 histiocytes, 5 DPE, (C) 3 - 
Presence of large foci of histiocytes and neutrophils within an area of hepatocellular loss 
and karyorrhectic debris, terminal animal. Images A-C stained with H&E, magnification 
600x with oil immersion. 
A B 
C 
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Figure 4: Viral inclusions and fibrin thrombi in liver of EBOV-infected Rhesus 
Macaques.  
(A) Cytoplasmic histiocytic viral inclusion, 3 DPE, (B) Hepatocellular cytoplasmic viral 
inclusions, 5 DPE, (C) 0 – Non-infected control animal stained with PTAH, no sinusoidal 
fibrin deposition visible, (D) 1 – Rare, multifocal occlusion of sinusoids by fibrin 
A B 
C D 
E F	
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thrombi, 4 DPE, (E) PTAH stain illustrating sinusoidal and venous fibrin thrombi, 
terminal animal, (F) Multiple sinusoidal fibrin thrombi, 6 DPE. Images A, B, D, & F 
stained with H&E, magnification 600x with oil immersion. Images C & E stained with 
PTAH, magnification 400x and 200x, respectively. 
 
 
		
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Progression of necrosis in liver of EBOV-infected Rhesus Macaques.  
(A) 0 - Non-infected control animal with normal hepatic architecture, (B) 1 - Rare single 
cell hepatocellular necrosis, 5 DPE, (C) 2 - Multifocal neighboring hepatocellular 
necrosis, 5 DPE, (D) 3 - Coalescing area of hepatocellular loss, terminal. Images A-D 
stained with Hematoxylin & Eosin (H&E). Magnification A, 400x; B-D, 600x with oil 
immersion. 
 
  
A B 
C D	
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Ordinal Histopathology Scoring 
 
Severity of necrosis, inflammation, fibrin deposition and overall cumulative 
histopathology scores were statistically significant among control and 3 DPE animals 
compared to terminal animals. Additional statistical significance was observed between 
necrosis in 4DPE and terminal animals; and fibrin deposition between 5 and 6 DPE 
animals compared to control and 3 DPE animals. Preliminary findings from H&E 
analysis informed separation of animals into peracute (3-4 DPE with a Cumulative Score 
< 4) and acute (5-6 DPE with a Cumulative Score > 4) as well as terminal (6-8 DPE) 
groups. These groups were defined based on observation of changes in histopathology 
relative to control animals that were mild versus moderate to severe in the liver of 
EBOV-infected rhesus macaques. 
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Figure 6: Semi-quantitative analysis of hepatic histopathology findings in EBOV-
infected Rhesus Macaques.  
(A) Inflammation, (B) Necrosis (C) Fibrin  
(D) Cumulative liver score calculated as the sum of the former three parameters, plus 1 if 
viral inclusions were present 
For all parameters, including overall score, there was a statistically significant difference 
across time points (P=0.0033; P=0.0042; P=0.0037; P=0.0045, Kruskal Wallis). 
Specifically, between individual time points, differences between control and terminal as 
well as 3 DPE and terminal groups were statistically significant (P < .05, Benjamin, 
Krieger and Yekutieli).   
*For each time point, the dashed line represents the mean, bars represent the standard 
deviation, and individual plot points represent the value for the given parameter for each 
animal at that time-	point. 
ns = non-significant P-value, *P-value < 0.05, **P-value < 0.005, ***P-value < 0.0005, 
****P-value < 0.00005. 
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mIHC Digital Image Analysis  
 
Independent Biomarker Immunoreactivity - Condition 1 
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Figure 7: Changes over time in area of hepatic tissue immunoreactive for VP35 
(Green), Tissue Factor (Red) and CD68 (Cyan).   
 
 
 
EBOV VP35 percent immunoreactivity ranged from a minimum of 0.037% 
(controls excluded; 0%) at 3 DPE to a maximum of 2.94% in a terminal animal. 
Intergroup statistical significance for VP35 was observed for terminal animals across all 
time points except for 6 DPE, and between control, 3 DPE and 4 DPE animals relative to 
5 DPE 
6 DPE 
Terminal 
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6 DPE animals (Figure 8A). TF percent immunoreactivity ranged from a minimum of 
0.0028% in a control animal and 0.0098% at 3 DPE to a maximum of 2.91% in a terminal 
animal. Statistical significance of terminal animals was observed when compared to all 
other groups ≤ 5 DPE (Figure 8B).  CD68 percent immunoreactivity ranged from 1.43% 
in a control animal to 7.7% in a 6 DPE animal. Statistical significance of terminal and 6 
DPE animals was observed when compared to all other groups ≤ 4 DPE (Figure 8C).  
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Figure 8: Temporal change in the total area % immunoreactivity of mIHC-1 viral 
and host biomarkers in the liver of Rhesus Macaques. 
(A) VP35 Assay 1, (B) Tissue Factor (TF), (C) CD68 
One-way ANOVA and post-hoc Tukey correction for multiple comparisons: 
P-value < 0.0001 for all analyses performed. Graphs indicate which groups showed 
statistically significant differences from one another for each marker. 
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Figure 9: Changes over time in number of cells per μm2 of hepatic tissue 
immunoreactive for CD68 (Macrophage marker).    
 
 
Number of cells per μm2 immunoreactive for CD68 ranged from 0.000278165 in a 
control animal to 0.001271192 in a 6 DPE animal. Statistical significance of terminal and 
6 DPE animals was observed when compared to all other groups ≤ 4 DPE as well as for 
control-3 DPE animals relative to 5 DPE animals (Figure 10). 
Terminal 
6 DPE 
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Figure 10: Temporal change in the number of cells per μm2 immunoreactive for 
CD68. 
One-way ANOVA and post-hoc Tukey correction for multiple comparisons: 
P-value < 0.0001. 
 
 
 
The increases in area quantification for CD68 over time and TF over time were 
directly correlated with changes in immunoreactivity for VP35 (r = 0.93; r = 0.87) and 
increases in CD68 and TF were also strongly correlated to each other (r = 0.85). As 
expected, colocalization was strongly correlated with increased in individual biomarkers 
over time. Additionally, AQ and HP module results for CD68 were very highly correlated 
(r = 0.98). 
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Table 8. Correlation Matrix for mIHC-1. 
 
  VP35 CD68 TF CD68 
& TF 
CD68 
& 
VP35 
TF & 
VP35 
CD68, 
TF & 
VP35 
VP35 1.00 0.93 0.87 0.83 0.91 0.81 0.78 
CD68 0.93 1.00 0.85 0.83 0.92 0.78 0.78 
TF 0.87 0.85 1.00 0.97 0.75 0.83 0.80 
CD68 & 
TF 
0.83 0.83 0.97 1.00 0.73 0.78 0.80 
CD68 & 
VP35 
0.91 0.92 0.75 0.73 1.00 0.86 0.88 
TF & 
VP35 
0.81 0.78 0.83 0.78 0.86 1.00 0.97 
CD68, TF 
& VP35 
0.78 0.78 0.80 0.80 0.88 0.97 1.00 			
Colocalization of Biomarker Immunoreactivity - Condition 1  
 
		 		 			
Figure 11: Colocalization of Tissue Factor, VP35 and CD68 at 6 DPE. 
In the same ROI, the red channel, visualizing TF, the green channel, visualizing EBOV 
VP35, and the cyan channel visualizing CD68 can be viewed independently and together 
to observe where dyes merge.  
(A) Red, (B) Red and green, (C) Red, green and cyan 
  
A B C 
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Colocalization of CD68 and TF (Figure 12A), as well as VP35 and TF (Figure 
12C), was statistically increased between peracute (3-4 DPE) and terminal (6-8 DPE) 
animals. Colocalization of CD68 and TF ranged from 0.0031% at in a control animal to 
1.16% in a terminal animal and colocalization of VP35 and TF ranged from 0.0000019% 
at 3 DPE to 0.61% in a terminal animal. Colocalization of CD68 and VP35 (Figure 12B) 
ranged from 0.0011% at 3 DPE to 0.96% in a 6 DPE animal and also increased 
significantly from peracute (control-4 DPE) to acute (5-6 DPE) and terminal (6-8 DPE) 
time points in the course of infection. Colocalization of all three biomarkers included in 
mIHC-1 ranged from 0.0000015% at 3 DPE to 0.28% in a terminal animal and increased 
significantly as well from peracute time points (control-4 DPE) when compared to both 6 
DPE and terminal animals (Figure 12D).  
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Figure 12: Temporal change in the colocalization of mIHC-1 viral and host 
biomarkers in the liver of Rhesus Macaques. 
(A) CD68 and Tissue Factor (TF), (B) CD68 and VP35, (C) Tissue Factor and VP35,  
(D) CD68, TF and VP35 
One-way ANOVA and post-hoc Tukey correction for multiple comparisons: (A) P-value 
= 0.006, (B) P-value < 0.0001, (C) P-value = 0.006, (D) P-value = 0.004 
 
 
 
Independent Biomarker Immunoreactivity - Condition 2 
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Figure 13: Changes over time in area of hepatic tissue immunoreactive for VP35 
(Green), Myeloperoxidease (Red) and Heppar (Cyan).  
 
 
EBOV VP35 percent immunoreactivity ranged from a minimum of 0.0021% 
(controls excluded; 0%) at 3 DPE to a maximum of 3.01% in a terminal animal. As in 
mIHC-1, intergroup statistical significance for VP35 was observed across all time points 
except for 6 DPE relative to terminal animals and between control, 3 DPE and 4 DPE 
animals relative to 6 DPE animals (Figure 14A). Myeloperoxidase (MPO) percent 
immunoreactivity ranged from a minimum of 0.21% in a control animal to a maximum of 
2.51% in a 6 DPE animal. Statistical significance of terminal and 6 DPE animals was 
observed when compared to all other groups ≤ 5 DPE and between control and 3 DPE 
animals relative to 5 DPE animals (Figure 14B). Heppar percent immunoreactivity 
ranged from 60.99% in a control animal to 40.07% in a terminal animal. Statistical 
significance was observed across all groups except for between 6 DPE and terminal 
animals (Figure 14C).  
Terminal 
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Figure 14: Temporal changes in the total area % immunoreactivity of mIHC-2 viral 
and host biomarkers in the liver of Rhesus Macaques. 
(A) VP35 Assay 2, (B) Myeloperoxidase (MPO), (C) Heppar 
One-way ANOVA and post-hoc Tukey correction for multiple comparisons:  
P-value < 0.0001 for all analyses performed.  
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Figure 15: Changes over time in number of cells per μm2 of hepatic tissue 
immunoreactive for MPO (Neutrophil marker).    
 
 
Number of cells per μm2 immunoreactive for MPO ranged from 0.000107156 in a 
control animal to 0.001078165 in a 6 DPE animal. Statistical significance of terminal and 
6 DPE animals was observed when compared to all other groups ≤ 4 DPE as well as for 
control-3 DPE animals relative to 5 DPE animals (Figure 16). 
 
Terminal 
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Figure 16: Temporal change in the number of cells per μm2 immunoreactive for 
MPO. 
One-way ANOVA and post-hoc Tukey correction for multiple comparisons: 
P-value < 0.0001. 
 
 
 
The decrease in Heppar area quantification over time was strongly correlated with 
changes in immunoreactivity for VP35 as was the temporal increase in MPO (r = -081; r 
= 0.88).	Changes in Heppar and MPO were also strongly negatively correlated to each 
other (r = -0.87). Additionally, AQ and HP module results for MPO were very highly 
correlated (r = 0.99). 
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Table 9. Correlation Matrix for mIHC-2. 
 
  VP35 Heppar MPO Heppar 
& VP35 
MPO & 
VP35 
VP35 1.00 -0.81 0.88 0.71 0.90 
Heppar -0.81 1.00 -0.87 -0.69 -0.74 
MPO 0.88 -0.87 1.00 0.75 0.77 
Heppar & 
VP35 0.71 -0.69 0.75 1.00 0.59 
MPO & 
VP35 0.90 -0.74 0.77 0.59 1.00 
 
Colocalization of Biomarker Immunoreactivity - Condition 2 
Colocalization of VP35 with both MPO and with Heppar, which may indicate 
viral infection of hepatocytes, was statistically increased between peracute (control-4 
DPE) and terminal animals. Colocalization of VP35 and MPO (Figure 17A) ranged from 
0.00051% at 3 DPE to 0.20% in a terminal animal. Colocalization of VP35 and Heppar 
(Figure 17B) ranged from 0.0040% at 3 DPE to 0.44% in a terminal animal.  
	55 
 
 
 
 
Figure 17: Temporal changes in the colocalization of mIHC-2 viral and host 
biomarkers in the liver of Rhesus Macaques. 
(A) Myeloperoxidase (MPO) and VP35, (B) Heppar and VP35  
One-way ANOVA and post-hoc Tukey correction for multiple comparisons: (A) P-value 
= 0.0017, (B) P-value = 0.0073 
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Figure 18: Changes in mIHC-2 results from 3 DPE to Terminal animals. 
(A) 3 DPE animal showing presence of neutrophils (MPO) in hepatic sinusoids with rare 
observation of VP35, (B) 4 DPE animal showing rare colocalization of VP35 and Heppar 
and increased VP35 immunoreactivity, (C) Terminal animal showing even more 
pronounced immunoreactivity for VP35 confined predominantly to the sinusoidal 
compartment.  		
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Figure 19: Changes over time in area of hepatic tissue hybridized for VP35 (Green), 
IL-6 (Red), and ISG-15 (Cyan) genes.  	
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EBOV VP35 hybridization ranged from a minimum of 0.0316% (controls 
excluded; 0%) at 3 DPE to a maximum of 2.70604% in a terminal animal. Intergroup 
statistical significance for VP35 expression was observed across peracute and 6 DPE 
animals as well as between control and terminal animals (Figure 20A).  Interleukin-6 (IL-
6) hybridization ranged from a minimum of 0.00203% in a control animal and 0.00956% 
at 3 DPE to a maximum of 1.01279% in a terminal animal. Statistical significance of 
terminal animals was observed when compared to all peracute groups (Figure 20B). 
Interferon-stimulated gene-15 (ISG-15) hybridization ranged from a minimum of 
0.00000643% in a control animal and 0.0211% at 3 DPE to a maximum of 1.47283% in a 
6 DPE animal. Statistical significance of 6 DPE animals was observed when compared to 
all other groups, including terminal animals, and statistical significance was observed 
between peracute and terminal animals as well as between control-3 DPE and 5 DPE 
animals (Figure 20C).  
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Figure 20: Temporal changes in the total area quantification of viral and host gene 
expression in the liver of Rhesus Macaques. 
(A) VP35, (B) Interleukin-6 (IL-6), (C) Interferon-stimulated Gene-15 (ISG-1) 
One-way ANOVA and post-hoc Tukey correction for multiple comparisons:  
A) P-value = 0.0013, B) P-value = 0.0072, (C) P-value < 0.0001 
 
 
 
Table 10. Correlation Matrix for FISH. 
  VP35 ISG-15 IL-6 ISG-15 
& IL-6 
ISG-15 
& VP35 
IS-15, IL-6 
& VP35 
IS-15, IL-6 
& VP35 
VP35 1.00 0.75 0.38 0.19 0.52 0.77 0.60 
ISG-15 0.75 1.00 0.63 0.67 0.78 0.83 0.90 
IL-6 0.38 0.63 1.00 0.74 0.83 0.72 0.68 
ISG-15 & 
IL-6 0.19 0.67 0.74 1.00 0.68 0.56 0.82 
ISG-15 & 
VP35 0.52 0.78 0.83 0.68 1.00 0.84 0.72 
IL-6 & 
VP35 0.77 0.83 0.72 0.56 0.84 1.00 0.82 
IS-15, IL-6 
& VP35 0.60 0.90 0.68 0.82 0.72 0.82 1.00 
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Simple linear regression indicates that only ISG-15 positively predicts increased 
hybridization for VP35 (Figure 21), and there is a stronger correlation between ISG-15 
and VP35 (r = 0.75) than when comparing IL-6 and VP35 (r = 0.38). ISG-15 and IL-6 
were also positively correlated with each other (r = 0.63).   
 
 
Figure 21: Simple linear regression of FISH host biomarker gene expression on 
EBOV VP35 viral marker expression. 
IL-6: %VP35 = 0.1333*(%IL-6) + 0.1035, R-square = 0.1460, P-value = 0.0964 
ISG-15: %VP35 = 0.4211*(%ISG-15) + 0.1248, R-square = 0.5655, P-value = 0.0001 
 
 
 
Colocalization of Biomarker Hybridization 
Colocalization of ISG-15 and IL-6 hybridization was prominent in peri-portal 
areas in acute and terminal disease (Figure 23) and was statistically increased between 
control-3 DPE and terminal animals. Colocalization of ISG-15 and IL-6 hybridization 
ranged from 0.00% in a control animal and 0.000134% at 3 DPE to 0.0877% in a 
terminal animal (Figure 22A). Colocalization of both ISG-15 and VP35 hybridization as 
well as IL-6 and VP35 hybridization were significantly increased between peracute and 6 
1 2 3
-0.5
0.0
0.5
1.0
1.5
2.0
% area VP35 hybridized
IL-6
ISG-15
	62 
DPE-terminal animals as well as between 5 DPE and terminal animals. More rare 
colocalization of ISG-15 and VP35 hybridization ranged from 0.00000432% at 3 DPE to 
0.0352% in a terminal animal (Figure 22B). More frequent colocalization of IL-6 and 
VP35 hybridization ranged from 0.000803% at 3 DPE to 0.200183% in a terminal animal 
and also increased significantly from 5 to 6 DPE (Figure 22C). While also more rare, 
colocalized hybridization of all three genes included in FISH did occur and ranged from 
0.0000016% at 3 DPE to 0.0116% in a 6 DPE animal. Colocalization of ISG-15, IL-6 and 
VP35 increased significantly from peracute time points (control-4 DPE) when compared 
to both 6 DPE and terminal animals as well as from 5 to 6 DPE and from 6 DPE to 
terminal animals (Figure 22D).  
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Figure 22: Temporal changes in the colocalization of viral and host biomarker gene 
expression in the liver of Rhesus Macaques. 
(A) ISG-15 and IL-6, (B) ISG-15 and VP35, (C) IL-6 and VP35, (D) ISG-15, IL-6 and 
VP35 
One-way ANOVA and post-hoc Tukey correction for multiple comparisons:  
(A) P-value = 0.0182, (B) P-value = 0.0003, (C) P-value < 0.0001, (D) P-value < 0.0001 
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Figure 23: Changes in FISH observed quantitiatively and qualitatively over time.  
(A) Small aggregate of ISG-15 hybridized cells visible in 3 DPE animal (Ordinal Score-
1), (B) Larger cluster of ISG-15 hybridized cells (Ordinal Score-2) with visible 
colocalization of IL-6, (C) Diffuse global ISG-15 hybridization (Ordinal Score-3) in a 5 
DPE animal, (D) Visualization of only the red channel (IL-6), (E) Colocalization (yellow) 
of IL-6 within VP35 hybridized cells, (F) Separation of channels shows colocalization of 
IL-6 and VP35 hybridization, but no observed colocalization of ISG-15 and VP35 
hybridization.  
 
 
 
Qualitative Findings for Biomarker Hybridization 
In Situ hybridization-positivity for EBOV VP35 was characterized by either 
generalized cytoplasmic signaling or intense discrete cytoplasmic foci interpreted to 
represent viral ribonucleoprotein complexes. Hybridization was initially reserved to sinus 
histiocytes at 3 DPE (3/3), later observed within hepatocytes at 4 DPE (2/3), and 
ultimately within blood leukocytes, fibrovascular stroma (vascular smooth muscle, 
fibroblasts, myofibroblasts, & pericytes) and endothelium by 5 DPE (1/3). By 6 DPE, 
hybridization persisted within all of these anatomical compartments (9/9); however, was 
A B C 
D E F 
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more prominent in the fibrovascular stroma for terminal animals when compared to 
earlier time points. Only two animals had marked hepatocyte hybridization (≥30%) (5 
DPI & 6 DPI). Control animals (3/3) displayed no EBOV VP35 hybridization. 
In Situ hybridization-positivity for IL-6 mRNA was characterized by fine discrete 
cytoplasmic puncta. Hybridization was initially mild and restricted to sporadic sinus 
histiocytes, portal, and central fibrovascular stroma in both control and 3 DPE animals 
(6/6). By 4 DPE IL-6 hybridization progressed to moderate severity within the 
aforementioned compartments (2/3) and was first observed within the hepatic capsule 
(2/3). By 5 DPE hybridization progressed to marked severity (2/3), and first became 
apparent in blood leukocytes. There was an apparent decline in IL-6 hybridization for the 
8 DPE terminal animals when compared to all animals between 4-7 DPE. IL-6 
hybridization was never observed within hepatocytes (21/21). Colocalization of IL-6 and 
EBOV VP35 hybridization was most apparent within areas of hepatocellular necrosis 
containing intense cellular inflammatory infiltrate. 
ISG-15 hybridization was the most ubiquitous in reference to affected cell 
phenotypes. Hybridization was first observed at 3 DPE in scattered sinusoidal histiocytes 
(1), followed by clusters of ISG-15 hybridized histiocytes (2), and finally generalized 
global ISG-15 hybridization in histiocytes, hepatocytes, blood, biliary epithelium, and/or 
vascular compartments (3). Colocalization with EBOV VP35 was extremely rare; 
however, hybridization was frequently observed in close proximity to infected cells.
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Table 11. Semi-quantitative findings for FISH. 
 VP35 HYBRIDIZATION IL-6 HYBRIDIZATION ISG-15 HYBRID. 
TIME 
POINT blood 
sinus 
histiocytes hepatocytes 
endothelium 
and 
fibrovascular 
stroma 
blood sinus histiocytes hepatocytes 
endothelium 
and 
fibrovascular 
stroma 
capsule Ordinal Score 
CONTROL - - - - - + - + - 0 
CONTROL - - - - - + - + - 0 
CONTROL - - - - - + - + - 0 
3 DPE - + - - - + - + - 1 
3 DPE - + - - - + - + - 1 
3 DPE - + - - - + - + - 2 
4 DPE - ++ - - - + - ++ - 2 
4 DPE - ++ + - - ++ - ++ + 2 
4 DPE - +++ ++ - - ++ - +++ + 3 
5 DPE + +++ +++ + + +++ - +++ + 3 
5 DPE - ++ + - - ++ - ++ + 2 
5 DPE + ++ ++ + + +++ - +++ + 3 
6 DPE + +++ ++ + + +++ - +++ + 3 
6 DPE + ++ ++ + + +++ - +++ + 3 
6 DPE + +++ +++ + + +++ - +++ + 3 
TERMINAL 
- 6 DPE + ++ ++ + + ++ - ++ + 3 
TERMINAL 
- 6 DPE + +++ ++ ++ + ++ - ++ + 3 
TERMINAL 
- 7 DPE + +++ ++ ++ + +++ - ++ + 3 
TERMINAL 
- 7 DPE + ++ ++ ++ + ++ - ++ + 3 
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TERMINAL 
- 8 DPE + ++ + ++ + ++ - + + 3 
TERMINAL 
- 8 DPE + ++ ++ ++ - ++ - + + 3 
+,	EBOV	RNA-	positive	cells	or	hybridization	in	specified	compartment	were	rarely	detected;	++,	EBOV-positive	cells	and/or	compartment-
specific	hybridization	were	occasionally	detected;	+++,	EBOV-positive	cells	and/or	compartment-specific	hybridization	were	frequently	
detected;	−,	no	EBOV-positive	cells	or	hybridization	in	specified	compartment	were	detected
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Comparison of Findings from Brightfield, mIHC and FISH	
Percent total area immunoreactivity for VP35 in mIHC-1 and mIHC-2 for serial 
liver sections collected from each animal was compared via paired t-test and showed no 
statistically significant difference (P-value < 0.0001) indicating that thresholds across the 
AQ modules used for the green channel, which was used to visualize VP35, were highly 
precise. Very strong positive correlation was also indicated by the Pearson correlation 
coefficient (r = 0.9909 and P-value < 0.0001) (Appendix III). For all biomarkers except 
Heppar, there was no statistically significant change in peracute animals (control-4 DPE) 
indicating that increase in percent immunoreactivity for VP35 and strongly correlated 
changes in CD68, MP, and TF do not occur until between 4 and 5 days post-infection.  
 
 
  
 
 
Figure 24: Simple linear regression of mIHC host biomarker immunoreactivity on 
EBOV VP35 viral marker immunoreactivity.  
Equations included in Appendix IV. All P-values < 0.0001. 
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Across mIHC conditions 1 and 2, simple linear regression showed a statically 
significant (P-value < 0.0001) relationship between all markers, including MPO, and 
percent VP35 immunoreactivity (Figure 24). All host biomarker variability across and 
within groups for each time point can partially predict variance in VP35 (R square > 
50%, P-value < 0.0001).  
The only 3 DPE animal with viral inclusions observed in histiocytes during 
histopathological analysis also had the highest percent of colocalization of VP35 and 
CD68 of any of the 3 DPE animals, (0.0039%) and had a higher percent tissue 
immunoreactivity for CD68 (2.38%), although not for VP35. Hepatocytic inclusions 
became apparent at 5 DPE histopathologically, when percent colocalization of Heppar 
and VP35 was also first measured to be statistically significant (0.20% and above 
although one 4 DPE animal with 0.25% merging did not get evaluated as having viral 
inclusions).  
Increases in individual host biomarkers were not consistently matched to 
increases in cumulative liver ordinal scores (i.e., some animals with higher scores had 
lower percent area immunoreactivity for associated biomarker(s) relative to animals with 
a lower score) but overall statistical trends, from simple linear regression (Appendix IV) 
and testing for correlation (Table 12), indicated a strong positive predictive relationship 
between histopathological, immunohistochemical, and In Situ hybridization findings.  
Pearson’s correlation coefficient confirmed that all biomarkers were strongly 
correlated with histopathology scores for necrosis, inflammation, and fibrin deposition as 
well as cumulative liver score (r > 0.5; p < 0.001). ISG-15 was most strongly correlated 
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with CD68 (r=0.83) and also strongly correlated with MPO (r = 0.78). IL-6 was most 
strongly correlated with VP35 and TF (r = 0.74; r = 0.73) while least correlated with 
VP35 hybridization (r = 0.38; P value < 0.05). Both MPO and CD68 were very strongly 
correlated with not only each other (r = 0.95) but also overall liver score (r = 0.0.83; r = 
0.84). Heppar was also strongly correlated to cumulative score (r = -0.90) and was 
negatively correlated with MPO (r=-0.89). Increase in VP35 over time was also very 
strongly correlated with Necrosis Score (r = 0.91) and CD68 (r = 0.90) and strongly 
correlated with all other host biomarkers and ordinal scores (r > 0.50). 
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Table 12. Heat map of correlation coefficients for ordinal semi-quantitative and continuous quantitative results. 
 
  
Ordinal 
Liver 
Score 
Necrosis 
Score 
Inflamm. 
Score 
Fibrin 
Score VP35 Heppar MP CD68 TF VP35 ISG15 IL6 
Ordinal 
Liver Score 1.00 0.85 0.92 0.91 0.79 -0.90 0.83 0.84 0.73 0.73 0.72 0.65 
Necrosis 
Score 0.85 1.00 0.88 0.88 0.91 -0.83 0.87 0.87 0.83 0.79 0.64 0.60 
Inflamm. 
Score 0.92 0.88 1.00 0.90 0.84 -0.83 0.88 0.87 0.79 0.77 0.68 0.68 
Fibrin 
Score 0.91 0.88 0.90 1.00 0.80 -0.84 0.85 0.83 0.77 0.80 0.74 0.65 
VP35 0.79 0.91 0.84 0.80 1.00 -0.81 0.88 0.90 0.87 0.78 0.63 0.74 
Heppar -0.90 -0.83 -0.83 -0.84 -0.81 1.00 -0.89 -0.84 -0.81 -0.71 -0.77 -0.64 
MP  0.83 0.87 0.88 0.85 0.88 -0.89 1.00 0.95 0.84 0.89 0.78 0.59 
CD68 0.84 0.87 0.87 0.83 0.90 -0.84 0.95 1.00 0.84 0.89 0.83 0.66 
TF 0.73 0.83 0.79 0.77 0.87 -0.81 0.84 0.84 1.00 0.61 0.59 0.73 
VP35 0.73 0.79 0.77 0.80 0.78 -0.71 0.89 0.89 0.61 1.00 0.75 0.38 
ISG15 0.72 0.64 0.68 0.74 0.63 -0.77 0.78 0.83 0.59 0.75 1.00 0.63 
IL6 0.65 0.60 0.68 0.65 0.74 -0.64 0.59 0.66 0.73 0.38 0.63 1.00 
 
	 73 
Observation of area quantification (AQ) over time post-infection showed a trend 
of increasing inflammation in the liver of EBOV-infected rhesus macaques, indicated by 
a statistically significant rise in percent total area immunoreactivity for macrophage 
(CD68), Tissue Factor (TF), and neutrophil (MPO) biomarkers. This was also confirmed 
via cell phenotyping, with an increase in number of neutrophils (cells positive for MPO) 
and macrophages (cells positive for CD68) measured per µm² over time, and correlates 
with hepatic inflammation, as indicated via analysis of H&E. Increased Tissue Factor, 
also indicative of inflammation, was measured via AQ at earlier time points (starting at 3 
DPE) than fibrin deposition was observed histopathologically (4 DPE and later).  
Comparing sections used in histopathological analysis and mIHC, visible 
increases in size and frequency of histiocytic aggregates and colocalization within 
aggregates of CD68 and VP35 occurred over time, as Necrosis Score increased (Figure 
25).  
 
     
 
Figure 25: Temporal progression of necrosis severity and % immunoreactivity for 
biomarkers. 
(A) 5-DPE, Necrosis-1, (B) 6 DPE; Necrosis-2, (C) Terminal; Necrosis-3 
 
	B C 
A B C 
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DISCUSSION 
 
 
Use of DIA as a Tool for EBOV Pathogenesis Research 
 
Previous research has led to important findings concerning NHP host-response to 
EBOV, confirming virulence and identifying tissue tropism and sites of viral persistence 
(Geisbert et al., 2003a, Geisbert et al., 2003b; Cooper et al., 2018; Chugtai et al., 2016). 
However, pathology studies have primarily been restricted to terminal animals dictated 
by pre-determined clinical endpoints and use of semi-quantitative or descriptive 
qualitative approaches. Specifically, immunohistochemical analysis has traditionally 
relied on methods that are not easily reproducible including qualitative descriptions of 
immunoreactivity, semi-quantitative ordinal scoring or categorical definitions (rare, 
moderate, frequent), qualitative cell phenotyping (i.e. cognitive application of histology 
knowledge in the context of differential nuclear counterstains) and manual cell counting, 
which is extremely time intensive and prone to observer bias and variability in reporting 
(Fedchenko & Reifenrath, 2014).  
 This was the first study that quantitatively evaluated temporal dissemination of 
EBOV infection within distinct anatomical compartments of the liver combined with 
quantitative and qualitative spatial analysis of the pro-inflammatory cytokine IL-6 and the 
interferon-stimulating gene ISG-15 by utilizing digital image analysis (DIA) on whole 
slide images (WSI). In comparison to qualitative analysis, DIA enables researchers with 
more reproducible and robust datasets that are amenable to statistical analysis and 
comparison with other study datasets (Snead et al., 2016; Rizzardi et al., 2012). Snead et 
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al. (2016) reviewed 3017 cases across surgical subspecialties, which were evaluated by 
17 pathologists via DP, and compared results to previous analysis via routine brightfield 
microscopy, evaluated by the same or different pathologists. Results were within the 95% 
confidence interval for intra-observer and inter-observe variability, indicating there was 
no statistically significant difference between DP and legacy brightfield analysis for 
histopathological diagnosis in the majority of cases. Rizzardi et al. (2012) compared IHC 
staining results for tissue microarrays from 215 ovarian serous carcinoma specimens 
using DIA and semi-quantitative visual scoring. They found strong agreement between 
classification of carcinomatous areas through DIA and manual annotation, confirmed via 
Spearman correlations. Previous reviews have also found that DIA makes it feasible to 
decipher subtle and minute changes, which potentially could reflect magnitudes of 
biological difference, through the generation of continuous variable data. An example 
includes measurement of the number or area of infiltrating leukocytes in wild-type versus 
knock-out mice for a specific gene linked to development of an autoimmune disorder, 
rather than having to rely on qualitative evaluation of global severity of inflammation 
(Webster & Dunstant, 2014). DIA also greatly improves efficiency and reproducibility of 
analysis, since modules are semi-automatic and analysis algorithms/parameters can be 
shared for reuse within and across studies. However, use of DIA has primarily been 
limited to studies of cancers and neurological disorders and there is not yet significant 
evidence for its utility in infectious diseases research (Rizzardi et al., 2012).  
To improve our understanding of the applications of DIA for EBOV pathogenesis 
research, we supplemented descriptive ordinal and qualitative pathology workflows with 
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digital pathology, image analysis, mIHC, and mFISH. Using DIA, we were able to 
measure statistically significant quantitative temporal changes in WSIs of liver from 
EBOV-infected rhesus macaques during peracute (3-4 DPE), acute (5-6 DPE), and 
terminal (6-8 DPE) infection that would not have been feasible to capture with 
qualitative observational analysis alone, including phenotyping and colocalization of 
biomarkers over time. Our research highlights the potential benefits of and challenges 
encountered in applying DIA to infectious disease pathogenesis research. 
In comparing our histopathological ordinal findings to those acquired via DIA, the 
limitations of observational analysis become apparent. Our scale for our ordinal data was 
developed through user-defined criteria that we subjectively interpreted to represent the 
global study variability, rather than continuous and precise measurements of specific 
compartments and/or cell types of interest. In addition, ordinal scoring does not represent 
a true linear relationship for temporal changes (e.g., the difference between a score of “1” 
and “2” is not necessarily of the same magnitude as the difference between a score of “2” 
and “3”). For example, in our ordinal scoring, necrosis scores of 1 or 2 represent evident 
ongoing hepatocyte necrosis, as depicted by hypereosinophilic cytoplasm and pyknotic 
nuclei, whereas a score of 3 represents large areas of hepatocellular loss, with minimal 
active hepatocyte necrosis. The same goes for our inflammation scores, where scores of 1 
and 2 represent sinusoidal expansion by histiocytes whereas a 3 is representative of 
inflammatory aggregates in areas of necrosis with significant infiltration of neutrophils.  
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Digital Image Analysis for mIHC: Findings and Limitations 
Using DIA, we were able to objectively and precisely measure changes in cell 
populations as relates to EBOV pathogenesis, including inflammation and necrosis, over 
time. With area quantification and cell phenotyping, we detected changes during peracute 
and acute infection that did not appear significant via qualitative or semi-quantitative 
observation alone. Ordinal scores for liver inflammation, fibrin thrombi, hepatocellular 
necrosis and cumulative score increased substantially but not significantly from 4-5 DPE. 
Using the more sensitive area quantification DIA module we were able to detect 
statistically significant changes not reflected by ordinal scores in percent positive 
immunoreactivity for CD68, TF, MPO and Heppar and probe hybridization for IL-6 and 
ISG-15 from peracute to acute and terminal EBOV infection.  
Dissemination of EBOV to the liver did not become histopathologically evident 
until approximately 4 DPE, although it was detected via mIHC and mFISH at 3 DPE. We 
first detected EBOV immunoreactivity free in sinusoids and in sinusoidal histiocytes at 3 
DPE, which increased significantly from peracute to acute and terminal infection. We 
found that temporal increase in EBOV immunoreactivity was positively correlated with 
acute and terminal increases in neutrophils and macrophages within the liver (statistically 
significant increase in MPO in 5 DPE-terminal animals; significant increase in CD68 in 6 
DPE and terminal animals; increased inflammation score) and overexpression of Tissue 
Factor (significant increase in terminal animals; further correlated with increased fibrin 
score). Whether increasing numbers of macrophages represent kupffer cell hyperplasia 
and/or migration of non-resident macrophages to the liver post-infection could not be 
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determined given that CD68 is non-specific and expressed on the membrane of all 
monocyte lineage cells. Increase in EBOV immunoreactivity was negatively correlated 
with necrosis of hepatocytes (i.e. statistically significant decrease in Heppar across all 
time points; increased necrosis score). We also measured a high correlation between 
increased immunoreactivity for MPO and decreased reactivity for Heppar, which reflects 
that neutrophils, which are phagocytic innate immune cells, are likely being recruited to 
sites of necrosis in the liver to clean up necrotic cellular debris (Lämmerman, 2016). 
In our study, while all biomarkers related to inflammation were found to increase 
significantly, via both AQ as well as HP analysis where applicable, there was the most 
inter-group frequency of statistical significance for temporal increase in 
immunoreactivity for TF, with significant changes observed even when comparing 5 DPE 
to terminal animals. This correlates with our observational findings, in which fibrin score 
was most sensitive for detecting inter-group variations, showing DIA is able to accurately 
recapitulate observational analysis while also highlighting the ability of DIA to better 
establish statistical significance relative to ordinal scoring.  
Our finding that loss of hepatocytes (decrease in Heppar immunoreactivity) was 
statistically significant across all time points, even between control and 3 DPE animals, 
and was inversely correlated with number of neutrophils and histiocytes, which were both 
strongly positively correlated with increased necrosis score over time, indicates that 
necrosis is an early and sustained effect of EBOV infection in the liver. Again, our DIA 
results for necrosis correlated strongly with our observational finding that necrosis score 
was the second most sensitive to inter-group variation and provide additional measures of 
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statistical significance not captured through ordinal scoring. While hepatocellular 
necrosis has been established as a histologic hallmark of EBOV in NHPs and other 
animal models (Geisbert et al., 2003a; Cooper et al., 2018), no study has used IHC to 
quantify hepatocellular loss over time following EBOV infection by displaying temporal 
loss of immunoreactivity to a liver-specific antigen (Heppar). 
Our findings are consistent with past IHC research, which has reported presence 
of EBOV in sinusoidal histiocytes starting at 3 DPE, an increase in macrophages, 
neutrophils and TF over time, and small foci of hepatocellular necrosis in the liver of 
humans and NHPs with fatal or acute EBOV (Geisbert et al., 2003a; Geisbert et al., 
2003b; Wyers et al., 1999). Previous studies have reported that neutrophilia is associated 
with fatal outcomes of EBOV in humans as well as cynomolgus macaques and rhesus 
macaques (McElroy et al, 2019; van der Ven et al., 2015; Geisbert et al., 2003a). Geisbert 
et al. (2003a) observed neutrophilia occurring from 1 to 4 days post-infection via 
hematology with increased cell count persisting through 6 DPE as well as observing 
increased neutrophils in hepatic sinusoids and central veins beginning at 4 DPE in 
cynomolgus and rhesus macaques. Our quantitative analysis further substantiates these 
findings and supports that an increased tissue demand of the liver is in part responsible 
for neutrophilia. Geisbert et al. (2003b) also described significant overexpression of TF in 
cynomolgus macaques using hematology, found via transmission electron microscopy 
that this increased TF expression was associated with macrophages, and qualitatively 
described and observed fibrin deposition associated with EBOV-infected macrophages in 
response to infection (2003a). 
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Certain studies on EBOV pathogenesis using traditional methods did not observe 
inflammatory infiltration in the liver or claimed that there was only minimal 
inflammation of EBOV-infected NHPs (Ryabchikova et al, 1999, Martines, 2015). 
Similarly, we could not establish statistical significance for semi-quantitative 
inflammation scores except when comparing peracute and terminal animals. By using 
DIA, we were able to measure significant changes across additional time points and for 
specific cell types, which highlights that the small but significant changes in 
immunoreactivity that we measured can be difficult to capture accurately through 
qualitative and semi-quantitative approaches.  
We could not establish statistical significance when comparing controls to 
peracute animals for biomarkers, even when employing DIA. This is in part attributed to 
the small sample size of this study. NHPs, while the gold standard for EBOV 
pathogenesis research, are expensive, require special facilities and housing, additional 
training of personnel, and present distinctive ethical challenges when compared to 
rodents leading, which contributed to our small sample size (Siragam et al., 2018; St. 
Claire et al., 2017). However, our results clearly do indicate a measurable, although not 
statistically significant, increase in immunoreactivity for all biomarkers beginning as 
early as 4 DPE and steadily growing by orders of magnitude across subsequent days post-
exposure, which is further reflected by increased inflammation score over time. These 
findings are also supported by and build upon previous histopathological research in 
EBOV-infected green monkeys and baboons, which showed increased severity of 
hepatocellular damage beginning at 4 DPE and continuing to worsen through 6 DPE, 
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with much less severe changes observed at 3 DPE (Ryabchikova et al., 1999).  
We could not apply cell phenotyping modules to evaluate viral colocalization 
within cell subsets because we elected to train algorithms to minimize false positives and 
found that this compromised our sensitivity and underestimated the biology we were 
characterizing. Thus, we instead relied on a less complex but more specific tool in area 
quantification (AQ). Using AQ, we found that colocalization of CD68 and VP35 
immunoreactivity were significantly increased from peracute to acute and peracute to 
terminal infection and that increases in immunoreactivity for CD68 and VP35 are 
furthermore highly correlated, as indicated by Pearson’s correlation coefficient. We 
additionally found a highly positive correlation between TF and CD68, as well as TF and 
VP35, and a statistically significant increase in colocalization over time for these 
biomarkers. We also found that increase in colocalization of MPO and VP35 
immunoreactivity, while not as large as that seen for CD68 and VP35, was statistically 
significant over time. 
While we cannot definitively report that colocalization represents biological 
processes occurring in the same cell of interest given the inherent resolution limitations 
afforded by standard microscopy, previous research supports the conclusion that 
increased colocalization of CD68 and VP35 does in fact represent a trend of increasing 
infection of macrophages by EBOV. Macrophages have been shown to support viral 
replication and are infected early on after EBOV exposure (Geisbert et al., 2003a).  
Geisbert et al. (2003a) found that macrophages in the liver were immunoreactive for 
EBOV starting at 3 DPE and increased numbers of macrophages were infected from 4 
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DPE onwards relative to earlier time points. This study did not provide quantitative 
findings but instead categorized immunoreactivity as “never”, “rarely”, “occasionally”, 
and “frequently” detected in cells.   
Significant correlation of TF, CD68 and VP35 can be explained by 
acknowledging that TF is expressed on the membrane of activated CD68 positive cells 
and is overexpressed during EBOV because VP35 indirectly activates the extrinsic 
coagulation pathway through activation of macrophages. Specifically, EBOV GP 
interacts with TLR4 on the macrophage cell membrane during cell entry, leading to 
induction of a pro-inflammatory response that includes increased IL-6 and TF expression 
(Geisbert et al., 2003b; Olejnik et al., 2017; Okumara et al., 2010; Lai et al., 2017). 
Although neutrophils have not been shown to support EBOV replication, they have been 
found to be susceptible to infection and modulate the host immune response 
(Mohamadzadeh et al., 2006) and therefore colocalization of MPO and VP35 could 
represent increase in number of infected neutrophils over time. However, free 
extracellular EBOV has been described within hepatic sinusoids and increased 
colocalization could simply reflect the fact that increased numbers of neutrophils were 
observed over time (Geisbert et al, 2003a; Ryabchikova et al., 1999). 
Observational analysis of our stained WSIs did indicate that during peracute 
infection EBOV was predominantly present extracellularly within sinusoids and in 
sinusoidal histiocytes and a relatively modest number of hepatocytes were infected even 
during acute and terminal disease. This was confirmed via AQ, which measured more 
macrophages than hepatocytes immunoreactive for VP35, and detected relatively small 
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changes in colocalization of immunoreactivity over time in comparison to more 
substantial changes for individual biomarker immunoreactivity. This finding supports 
previous semi-quantitative research in NHPs with occasional detection of 
immunoreactive kupffer cells starting at 3 DPE and frequent detection from 4-6 DPE, but 
only rare detection of immunoreactive hepatocytes starting at 4 DPE and occasional 
detection at 5-6 DPE (Geisbert et al., 2003a). Given that progressive hepatocyte necrosis 
is an established hallmark of EBOV (Marzi et al, 2015), our findings of statistically 
significantly decreasing Heppar immunoreactivity and an absence of substantial 
colocalization of Heppar and VP35 (maximum colocalization 0.4% in a terminal animal 
compared to 1.0% for CD68 and VP35) is reflected to confirm significant increase in Ca   
 
Digital Image Analysis for FISH: Findings and Limitations 
To date, RNA sequencing has been used to measure differential expression of 
cytokine and innate host immune response in EBOV using peripheral blood from 
naturally EBOV-infected humans or in experimentally inoculated NHPs. Acknowledging 
that RNA sequencing cannot provide spatial context of mRNA within tissue architecture, 
it is currently unknown which cell phenotypes drive differential cytokine and innate host 
responses in the context of EBOV (Geisbert et al., 2003a; Caballero et al., 2016; 
Speranza et al., 2018). While the mIHC results outlined confirm and expand upon 
existing histopathological and immunohistochemical analyses of EBOV-infected animals, 
the mFISH performed as part of this study and analyzed via DIA provides novel spatial 
insight into genes associated with the pro-inflammatory state and host innate response of 
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EBOV. 
The HaloTM module designed for FISH DIA was particularly difficult to fine-tune 
and, given our slide resolution (200x), we could not use it to count distinct puncti or 
number of hybridized cells for WSIs and instead had to rely on the more accurate but 
superficial level of analysis afforded by the area quantification module, which we 
supplemented with semi-quantitative observational analysis. Given the additional 
challenges of fine-tuning the AQ module for FISH analysis, we will also be working to 
validate our algorithms and make our FISH findings more reliable before further 
publication of our results discussed here. Using AQ, we were able to collect preliminary 
findings pertaining to changes in hybridization over time and, through a combination of 
DIA and qualitative analysis, we were able to capture colocalization by tissue 
compartment and cell phenotype.  
Hybridized tissue for VP35 mRNA was measured to significantly increase by 4 
DPE whereas percent tissue immunoreactivity for VP35 antigen was not significantly 
increased until greater than or equal to 6 DPE and after, relative to peracute animals. 
Additionally, we found that in terminal animals VP35 hybridization was decreased on 
average, although not statistically significantly different from, values seen at 6 DPE. This 
could indicate that viral load is no longer at its peak and replication has decreased. 
Furthermore, terminal animals have reached pre-determined endpoints, suggesting that 
progression of clinical disease is not entirely linked to viral load. ISG-15 and IL-6 were 
significantly increased from peracute to acute (6 DPE) infection but decreased on average 
from 6 DPE to terminal animals. IL-6 showed considerable variability in terminal 
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animals, with a much wider range of hybridization than at 6 DPE. While IL-6 was 
relatively frequently colocalized with VP35 in comparison with ISG-15, there was not 
strong correlation between percent hybridization for VP35 and IL-6.  Colocalization of 
ISG-15 with VP35 was extremely rare; however, ISG-15 hybridization was more 
frequently observed in close proximity to infected cells.  
Previous research also showed that EBOV mRNA was detected in cells that were 
negative for EBOV antigen at 2 DPE in the liver, consistent with our findings, and that 
VP35 hybridization subsequently increased at 3 and 4 DPE, but could not establish 
statistical significance due to use of ordinal scoring (Geisbert et al., 2003a). Peak viral 
load in EBOV-infected NHPs, including rhesus macaques, was also measured to occur 
between 5-7 DPE followed by a decrease in viremia at later time points, consistent with 
our finding of decreased average viral replication in terminal animals (Madelain et al., 
2018). Additionally, our observation of relatively infrequent VP35 and ISG-15 
colocalization and more frequent VP35 and IL-6 colocalization supports previous 
research wherein infection of permissive cells, specifically immortalized human hepatic 
cells (Huh7) and primary monocyte-derived dendritic cells (mdDC), by EBOV has been 
shown to promote interleukin expression, with significant levels at 4-5 DPE, and inhibit 
host interferon responses (Speranza & Connor, 2017). Previous research has also shown 
that viral infection triggers an uncontrolled pro-inflammatory response in NHPs and 
induces a cytokine storm, including upregulation of IL-6 expression, measured via 
hematology, which contributes to DIC and in severe cases, death (Madelain et al., 2018). 
In vivo research with rhesus macaques has also measured a strong increase in ISG-15 in 
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circulating immune cells as early as 2-4 DPE (Caballero et al., 2016). Caballero et al. 
(2016) found, via real-time PCR, that IFN and ISG levels peaked in the liver at 4 DPE 
and remained elevated throughout acute infection but only detected a statistically 
significant upregulation at 8 DPE. However, our findings indicate that in the liver this 
response significantly increases from as early as 4 to 6 DPE (peracute to acute infection).  
Caballero et al. (2016) hypothesized that upregulation of the innate immune 
response may be explained by bystander cell activation or mutations in VP35 that stop it 
from effectively blocking interferon response in infected cells. In using RNA extraction 
and sequencing, this and similar studies could not provide any information regarding 
localization within specific anatomical or cellular compartments of the liver. Our 
quantitative findings support the hypothesis put forth in previous research suggesting that 
following EBOV host cell infection, neighboring cells are capable of being appropriately 
primed to help mitigate further viral dissemination (Caballero et al., 2016; Speranza & 
Connor, 2017).  
Our qualitative findings indicate that peracutely IL-6 hybridization is found in 
sinusoidal histiocytes and, during acute infection, within the endothelium, fibrovascular 
stroma and hepatic capsule. The shift of VP35 from histiocytes and hepatocytes to 
fibrovascular stroma near the end of acute infection may represent an evolutionary 
adoption of EBOV aimed to enable viral persistence. A recent study conducted on rhesus 
macaques found via IHC analysis of the EBOV viral protein NP that viral persistence 
occurs in the eyes, brain and testes via vascular structures but did not find evidence of 
persistence in key sites of viral replication such as the liver (Zeng et al., 2017). Together, 
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our findings and past research could indicate that during acute infection, when viral 
replication has already peaked, EBOV is beginning to travel from primary sites of 
replication like the liver to tissues where viral persistence occurs. 
Future research using dual IHC-FISH staining could better link gene expression to 
specific tissue compartments and cell phenotypes. Further research is also required to 
evaluate effect of EBOV infection on host and bystander cells and viral persistence of 
EBOV, which will be a challenge given low survivability of NHPs post-EBOV infection 
(Madelain et al., 2018). However, there is ongoing research to address mortality rates in 
NHPs and work to more closely recapitulate lethality in humans using this animal model, 
including through mucosal inoculation, variable inoculation dose and concurrent use of 
MCMs (Claire et al., 2017; Alfson et al., 2015; Alfson et al., 2017; Dowall et al., 2017). 
 
Study Limitations 
We observed significant inter-slide variation in reference to fluorescence intensity 
among animals from the same treatment groups. Although our mIHC and ISH methods 
and image acquisition parameters were standardized, we interpret this observation to be 
multifactorial, resulting from a combination of pre-analytical and inherent biological 
variability. Several of the animals from this study reached terminal endpoints and were 
then euthanized at 6 DPE (n = 2), 7 DPE (n = 2), or 8 DPE (n = 3) while others were 
humanely euthanized at pre-determined time points. Time from death to tissue collection 
plays a critical role in the degree of tissue autolysis, of which the former is well 
established to influence downstream ancillary test results including IHC and ISH 
	 88 
(Kaushik et al., 2014; Rao, 2016). Furthermore, it is not known how long tissues were 
fixed in 10% neutral buffered formalin before being processed, which could potentially 
serve as an additional layer of variability that could have influenced results. Tris-based 
buffers were used to overcome the majority of negative side effects associated with 
longer fixation times, specifically RNA degradation, which has been well documented 
with prolonged fixation (von Ahlfen et al., 2007).  
Due to the global variation of fluorescent intensities across specimens, we were 
unable to run a single algorithm in batch mode across the entire study that we interpreted 
to accurately represent the biological processes we aimed to characterize. This problem 
was addressed in an iterative validation process that is described in our methods. While 
we were able to provide more robust and reliable histopathology results relative to studies 
conducted without DIA, we could not establish easily reproducible data. For results from 
DIA pathogenesis research to become more reproducible, it will be critically important to 
standardize and automate tissue processing, differential tissue labeling and image 
acquisition. Additionally, reproducibility will require further refinement of image 
analysis software to overcome the limitations we encountered that warranted application 
of iterative semi-manual algorithm development, for which a standard set of parameters 
cannot simply be shared and adopted for future research. 
Since our results are representative of a single 5 µm liver section from each of the 
21 rhesus macaques enrolled in this study, our findings may not fully capture the 
potential global variability within this organ; however, our findings still provide novel 
quantitative insights into the temporal dissemination of EBOV within the liver 
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complemented by host spatial gene expression. Additionally, while we showed 
significant correlation between various measured biomarkers and histomorphological 
changes, correlation does not necessarily equal causation. Correlations could be directly 
linked (cause-effect) or indirectly linked by an additional biological process not 
characterized through our employed methodologies.  Based on our approach, we cannot 
determine whether changes in one parameter directly caused changes in another and we 
cannot definitely conclude that merging of IHC and ISH biomarkers truly represented 
colocalization given the resolution limitations of epi-fluorescent microscopy. Future 
research investigating different combinations of biomarkers, comparing IHC and FISH 
results to clinical and hematological findings, and conducting dual IHC-FISH could 
provide additional insight into the relationship between host and viral biomarkers 
associated with EBOV pathogenesis in the liver. 
 
Implications and Future Research 
Although there were limitations to our research, given that HaloTM  has not 
previously been used for EBOV research, we were able to optimize and validate DIA 
algorithms to produce quantitative results, which were highly correlated with 
observational findings, and provide clear evidence that DIA has the potential to facilitate 
more rigorous and efficient analysis for infectious disease pathogenesis. Application of 
DIA to our mIHC and FISH slides allowed us to reliably define host-response to EBOV 
in rhesus macaques, which can inform future models of disease and development of 
MCMs.  
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DIA results from NHP EBOV pathogenesis studies can serve as a reference for 
and inform development of novel disease models such as PHH and iPSC-derived 
hepatocyte infection models, multicellular in vitro platforms, and synthetic organ 
platforms (i.e. vascularized micro-liver), that more accurately recapitulate EBOV relative 
to immortalized cell lines. Analysis of correlation can be employed through quantitative 
analysis to validate or disprove proposed biological processes described using in vitro 
platforms. These new liver tissue models, if shown via DIA to faithfully recapitulate 
EBOV-induced host responses in the liver of infected NHPs, could complement use of 
NHPs as a more cost-effective, ethical and accessible model for EBOV pathogenesis 
research and drive discovery for, help to refine or eventually even replace animal models 
(Bennett et al., 2017).  
Additionally, semi-quantitative ordinal scoring is not as effective a tool for 
precisely defining microscopic thresholds in pathogenesis studies because of the 
limitations previously discussed. Using DIA, thresholds representative of diagnostic or 
prognostic significance can be established through continuous quantitative datasets that 
are amenable to statistical analyses. Furthermore, these highly sensitive and quantitative 
thresholds can be used to investigate multi-institutional fidelity of NHP studies, or studies 
using other models for EBOV, among each other and in the context of natural disease in 
humans. DIA could even one day be used in experimental MCM studies to set thresholds 
for efficacy and precisely determine mechanism of action at the molecular level, which is 
required as part of pre-clinical development under the FDA’s “Animal Rule”, and for 
now can serve as high throughput screening platforms for drug candidates to then test in 
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animal models. Furthermore, DIA findings can be integrated with in vitro, omics, and 
other clinical and biological datasets, given their continuous quantitative nature, 
providing more robust and informative statistical information to confirm NHPs as an 
appropriate disease model and further accelerate MCM research. The NIAID IRF study, 
which provided our tissue samples, collected extensive data that will provide clinical, 
physiologic and gross findings that can then be integrated with our histologic data to 
inform model development for products requiring FDA approval. 
The “Animal Rule” requires a “sufficiently well-characterized animal model for 
predicting the response in humans” for a given disease in order to use that animal in 
MCM trials (FDA, 2005). In order to use rhesus macaques and other NHPs in animal 
studies for approval of any MCMs for EBOV, additional knowledge and evidence of 
disease pathology, as provided in this study through use of DIA, could be of value. 
Current research has been able to demonstrate similarities in EBOV pathogenesis 
between humans and NHPs but DIA has the ability to measure the same trends, and 
possibly lack of statistically significant differences for them, in humans versus NHPs.  
Although DIA is currently entirely a research tool and not yet validated or 
reproducible enough to use under Good Laboratory Practice (GLP), with further 
refinement and development DIA could one day become a useful approach for 
overcoming challenges to demonstrating MCM efficacy and mechanism of action to the 
degree required to gain approval under “Animal Rule”. For example, a recent study 
evaluated efficacy of a recombinant inhibitor of TF as a treatment in EBOV-infected 
rhesus macaques (Geisbert et al., 2003b), after in vitro research showed that EBOV-
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infected monocytes and macrophages overexpress TF (Geisbert et al., 2003b; Geisbert et 
al., 2003c). Using DIA, we were able to measure discrete changes in TF 
immunoreactivity within the liver over time and relate this to CD68 and VP35 
immunoreactivity. Future research could use cell phenotyping, once better optimized, to 
accommodate the heterogeneity of cell phenotypes observed in whole organs in order to 
evaluate changes in TF immunoreactivity as well as in the total number of CD68+ 
macrophages colocalized with and likely coexpressing TF in control versus treated 
animals. These findings could then also be related to changes in survival rates. This 
would provide spatial and visual evidence of the efficacy of a TF inhibitor in mitigating 
progression of EBOV across time points post-exposure, and potentially further accelerate 
its approval as a host-directed therapy for EBOV. 
Specifically for DIA of FISH, comparisons of hybridization patterns between 
sham and vaccine inoculated animals could one day help to fast-track vaccine approval 
under “Animal Rule”. Efficacy of the rVSV-EBOV vaccine, which produces EBOV GP 
to provoke a neutralizing immune response to infection, has been studied in NHPs using 
transcriptomics, which found via hematology that over 100 transcripts associated with the 
innate immune response, particularly ISGs, were differentially downregulated following 
vaccination (Menicucci et al., 2017). DIA of FISH could provide novel insights into the 
mechanism of action by which the vaccines alter the immune response in favor of the 
host following EBOV infection. This approach could also be of value in identifying 
which cell types drive the early immune response to EBOV infection. Findings could 
furthermore be used to develop treatments that target EBOV infection earlier on based on 
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cell-specific acute host responses. 
Our findings corroborate past research that has demonstrated NHP fidelity to 
human EBOV infection and pathogenesis and indicated NHPs as a reliable model for 
MCM research (Piorkowski et al., 2017; Zaki & Goldsmith, 1999). Given the rarity of 
EBOV infected human clinical tissue specimens and the fact that it is not ethical to 
conduct clinical research outside of naturally occurring outbreaks, this study has built on 
previous experimental NHP models of EBOV. We have integrated novel quantitative 
outputs using DIA to characterize the temporal dissemination of EBOV within distinct 
liver cellular compartments and to characterize spatial gene responses known to play a 
role in EBOV pathogenesis and host response.  
To further develop integration of DIA into pathology workflows for infectious 
disease research, Dr. Crossland has proposed a collaborative digital pathology pipeline 
for national and regional biocontainment laboratories. This pipeline would introduce 
cross-institution, cloud-based use of DIA. To date, for the most part, BSL-4 research has 
been siloed across the few institutions approved to work with category A bioterrorism 
agents like EBOV, leading to lack of standardization in interpreting and reporting of 
results and making it next to impossible to directly compare findings across studies 
conducted at different institutions (Fedchenko et al., 2014). Using DIA and shared 
algorithms, this can be overcome, particularly if pre-analytical standardization is 
improved through use of automated staining methods to minimize variability. Through 
sharing of results across a global network of institutions, analysis would be expedited, as 
would follow-up research.  
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Our findings provide new and significant details about EBOV pathogenesis and 
model development and refinement through the application of DIA. In comparing DIA to 
traditional models for histopathology, using findings from our own research as well as 
previous studies, we have shown that the value of DIA for infectious disease research 
could be exponential. DIA has the potential to reduce workload of analysis on veterinary 
pathologists, improve standardization and objectivity of results, foster collaboration and 
speed up research, and one day could contribute to development and approval of MCMs 
for urgent public health threats like EBOV.  
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Appendix I: Euthanasia Criteria 
 
  
PARAMETER DEGREE OF PARAMETER SCORE 
Overall clinical 
appearance; signs 
of hemorrhage 
Normal appearance, no petechial or ecchymotic 
hemorrhages 
Facial edema, photophobia, cyanosis, prolonged coagulation 
profile 
Severe diarrhea, vomiting, dehydration, petechiae 
Persistent epistaxis, melena, retrobulbar hemorrhage 
0 
2 
5 
10 
Respiratory rate, 
mucous 
membranes 
(MM) color, and 
Dyspnea 
(Difficulty 
breathing/labored 
respirations) 
Normal signs (Respiratory rate = 32 to 50 BPM; MM pink) 
Mild (Respiratory rate = 51 to 65 BPM, with slightly 
increased effort; MM pale pink) 
Moderate (Respiratory rate = 66 to 80 BPM, with obvious 
difficulty breathing; MM muddy pink) 
Severe (Respiratory rate = > 80 BPM; respirations labored; 
MM blue) 
0 
2 
  
7 
10 
Recumbency 
Normal – Not lying down when enter room 
Lying down when enter room but gets up readily when 
approached 
Lying down when enter room but gets up with stimulation 
at cage front 
Lies down; will not get up even with excessive stimulation at 
cage front 
0 
5 
8 
10 
Non-
Responsiveness 
Normal – bright, alert, responsive 
Mild, slightly depressed; slightly decreased appetite; puts 
head down when personnel in room; acts disinterested when 
personnel in room 
Moderately non-responsive; very disinterested in personnel; 
hunched or lying down; will get up when approached or 
prodded 
Severe; completely non-responsive to noxious stimuli such 
as toe-pinch; will not get up despite significant prodding 
0 
3 
  
5 
  
10 
Core temperature 
of anesthetized 
animal (Normal 
in non-
anesthetized 
macaque = 37 – 
39oC = 98.6 – 
102.2oF) 
  
>36.7oC (>98oF) 
36.7>X>33.8oC (98-93.3oF) 
<33.8oC (<93.2oF) 
  
0 
3 
10 
Clinical score   * 
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Appendix II: mIHC Condition – 3 
 
 
Table AI. Optimized conditions for mIHC-3. 
 
 
Primary 
Antibody 
Animal 
and 
Isotype 
Tissue 
marker 
Manufacturer, 
Catalog # and 
Lot # 
Conc. TSA-
conjugated 
Fluorochrome 
Manufacturer, 
Catalog # and 
Lot # 
Conc. AR 
VP35 Ms 
IgG2b 
EBOV 
Viral 
particles 
Kerafast 
EMS703 
090315 
1/300 Green PerkinElmer 
FP1487A 
2380385 
1/400 1 
CK19 
4E8 
Ms 
IgG1 
Oval cells, 
Biliary 
epithelium 
ThermoFisher 
MA5-15884 
TD2559278 
1/600 Far red PerkinElmer 
FP1497A 
2491340 
1/100 2 
Smooth 
Muscle 
Actin 
(1A4 
(asm-1)) 
Ms 
IgG2a 
Myofibrob
lasts, 
Smooth 
Muscle 
ThermoFisher 
MA5-11547 
TF2585891C 
1/600 Red PerkinElmer 
FP1488A 
2496488 
1/200 3 
 
 
Due to lack of staining specificity of Smooth Muscle Actin (SMA) in the red 
channel, quantitative digital image analysis was not performed for this assay. However, 
immunostained slides were scanned for observational analysis in HaloTM. There was no 
visible merging of VP35 and SMA until 6 DPE, indicating that smooth muscle cells 
surrounding vessels in the liver were not visibly infected with EBOV at earlier time 
points. Merging of VP35 and CK19 was visible in single cells at 6 DPE but there did not 
appear to be merging of VP35 and CK19 at biliary ducts. Without DIA it was not 
possible to assess the degree of colocalization for CK19, SMA, and VP35 and changes in 
colocalization over time or whether there was any increase in percent area 
immunoreactive for CK19, which might be indicative of oval cell hyperplasia within the 
liver. 
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Control     3 DPE  
    
4 DPE      5 DPE 
     
6 DPE      6 DPE; increased magnification 
   
Terminal     Terminal; Purple channel turned off 
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Figure AI. Changes over time in observation of VP35 (Green), Smooth Muscle Actin 
(Red) and CK19 (Cyan) in liver of EBOV-infected Rhesus Macaques. 
6 DPE image with increased magnification shows that, even with color deconvolution, 
SMA is not only staining smooth muscle cells but is also diffusely positive in 
surrounding hepatocytes, indicating lack of specificity that would distort AQ and HP 
results. 
Terminal image with purple channel turned off highlights lack of merging of CK19 and 
VP35 at biliary ducts. 
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Appendix III: VP35 mIHC-1 and mIHC-2 Correlation 
 
 
 
 
Figure: Correlation between percent total tissue area immunoreactive for VP35 in 
serial sections from assays 1 and 2.  
Pearson’s correlation coefficient (r) = 0.9909, P-value < 0.0001. 
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Appendix IV: Simple linear regression of results 		
Outcome 
 
Predictive 
Variable 
Regression Equation R-square P-value 
% VP35 
Immunoreactivity 
TF Y = 0.8072*X + 0.1046 0.7493 
 
<0.0001 
 
 CD68 Y = 1.775*X + 2.357 0.8533 <0.0001 
 MPO Y = 0.6417*X + 0.6753 0.8000 <0.0001 
 Heppar Y = -4.587*X + 52.54 0.6666 <0.0001 
 IL-6 Y = 0.1583*X + 0.04530 0.4014 0.0036 
 ISG-15 Y = 0.3398*X + 0.1513 0.6046 <0.0001 
Ordinal Liver Score VP35 Y = 0.2817*X - 0.2568 0.6392 <0.0001 
 Coloc. Of 
VP35, TF and 
CD68 
Y = 0.02310*X - 0.01521 
 
0.6710 
 
<0.0001 
 
 Coloc of 
VP35 and 
Heppar 
Y = 0.02407*X - 0.002129 
 
0.3990 
 
0.0028 
 
 IL-6 Y = 0.05835*X - 0.02923 0.4421 0.0014 
 ISG-15 Y = 0.1017*X + 0.04820 0.5217 0.0003 
Necrosis Score VP35 Y = 0.9780*X + 0.04399 0.8335 <0.0001 
 TF Y = 0.8319*X + 0.09976 0.6934 <0.0001 
 CD68 Y = 1.773*X + 2.401 0.7414 <0.0001 
 MPO Y = 0.6647*X + 0.6683 0.7478 <0.0001 
 Heppar Y = -4.955*X + 52.78 0.6777 <0.0001 
 Coloc of 
VP35 and 
Heppar 
Y = 0.07521*X + 0.02631 
 
0.3875 0.0034 
 
Inflammation Score VP35 Y = 0.8665*X - 0.1967 0.7095 <0.0001 
 TF Y = 0.7533*X - 0.1268 0.6165 <0.0001 
 CD68 Y = 1.743*X + 1.731 0.7776 <0.0001 
 MPO Y = 0.6529*X + 0.4183 0.7826 <0.0001 
 Heppar Y = -4.824*X + 54.59 0.6966 <0.0001 
Fibrin Score VP35 Y = 0.9403*X - 0.06119 0.6423 <0.0001 
 TF Y = 0.8378*X - 0.03155 0.5864 <0.0001 
 CD68 Y = 1.859*X + 2.040 0.6798 <0.0001 
 MPO Y = 0.7078*X + 0.5212 0.7070 <0.0001 
 Heppar Y = -5.451*X + 54.07 0.6840 <0.0001 	
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